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INTERROGATING DUX4 MRNA 3’END FORMATION

Natoya Janeen Peart, B.S

Advisory Professor: Eric J. Wagner, Ph.D.

Double Homeobox 4, Dux4, is the leading candidate gene for Facioscapulohumeral
Dystrophy (FSHD). FSHD is the third most common muscular dystrophy, and is
characterized by progressive muscle weakness primarily in the upper body. In individuals
diagnosed with FSHD, Dux4 is inappropriately expressed in somatic cells due to two
conditions. The first is hypomethylation of the subtelomeric D4Z4 repeats on chromosome 4.
Each D4Z4 repeat on chromosome 4 is 3.3kb in length and contains the open reading frame
for Dux4. Hypomethylation of the D4Z4 repeats primarily occurs due to contraction of the
repeats from 11-100 (typical numbers in the healthy population) to between 1 and 10
repeats. Concomitant with the hypomethylation of the D4Z4 repeats on chromosome 4 is a
single nucleotide polymorphism in the flanking DNA that generates a non-consensus
polyadenylation signal (PAS). This PAS allows for the productive transcription of a
polyadenylated Dux4 mRNA from the terminal D4Z4 repeat. Dux4 is anemically expressed
in patient somatic cells, but contributes to FSHD pathology due to Dux4-dependent cellular
reprogramming.
We aim to understand what regulatory elements facilitate the cleavage and
polyadenylation (CPA) of the Dux4 mRNA beyond the non-consensus PAS and to
determine if inefficient CPA underlies the poor expression of Dux4 in patient cells. We
vii

designed a transcriptional read-through reporter to assay cleavage and polyadenylation in
cells and confirm that additional cis elements are required for CPA of Dux4 besides the nonconsensus PAS. This element is located outside the region where cis regulatory elements
for CPA are usually present. Moreover, the element which lies downstream of the PAS, is
within a degenerate repeat region, called β-satellite DNA. Using the knowledge gained from
characterizing Dux4 mRNA 3′end formation, we designed antisense oligonucleotides
(ASOs) to impair the production of polyadenylated Dux4. Prior to antagonizing Dux4 CPA,
we demonstrate, in proof of principle experiments that ASOs directed toward required CPA
regulatory elements can impair gene expression, and may redirect polyadenylation. Finally,
the work presented here lays the foundation for us to impair Dux4 CPA in reporter driven
assays and patient cells; and to exploit currently available deep sequencing technology to
determine the specificity of PAS-directed ASOs.
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Chapter 1 : Eukaryotic RNA Processing
Whatever begins, also ends?
-Seneca the Younger

1

What is RNA Processing?
Ribonucleic Acid (RNA) is one the three major macromolecules important for life. In
eukaryotes, genetic material is stored in the deoxyribonucleic acid (DNA) and then
transmitted as RNA in response to stimuli, to catalyze reactions, regulate gene expression,
influence cell structure, and regulate cell behavior, in part through the translation of the RNA
into a protein. There are many types of RNA molecules and they serve important roles in the
eukaryotic cell. Here, I will provide background on RNA processing by focusing on RNA
transcribed by RNA Polymerase II (RNAPII). Specifically, I will focus on the maturation and
metabolism of the RNA accomplished through processing of the 3′ end in order to remove it
from the template DNA and package it for stability in the nucleus and ultimately cytoplasm.
Nuclear 3′ end RNA Processing
RNA polymerase II (RNAPII) is a large multi-subunit and tightly regulated enzyme
responsible for producing messenger RNA (mRNA), and several non-coding RNA (ncRNA)
including some microRNAs (miRNAs), small nucleolar RNAs (snoRNAs) and small nuclear
RNAs (snRNAs). Post translational modifications which regulate the function of RNAPII
occur on the highly conserved C-terminal domain (CTD) and take the form of various
phosphorylation events which facilitate initiation, elongation and termination of transcription
(Hampsey, 1998; Jeronimo et al., 2013; Mayfield et al., 2016). For initiation of transcription,
RNAPII associates with various factors ranging from the general transcription factors (for
initiation of transcription of mRNAs) to specific transcription factors such as small nuclear
RNA activating protein complex (for transcription initiation of snRNAs) (Chen and Wagner,
2010; Gupta et al., 2016). Following the initiation of transcription and the synthesis of
nascent RNA, all RNA transcripts have a 5′ triphosphate. Typically, RNAPII transcripts
undergo additional modification to protect the RNA, by addition of an inverted N7-
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methylguanosine (m7G) to the 5′ terminus of the RNA (Byszewska et al., 2014), which ‘caps’
the RNA. Subsequent to capping and during the elongation of the RNA transcript, additional
processing occurs co-transcriptionally to yield a mature RNA product. For example, the
majority of eukaryotic mRNAs are spliced to remove introns. However, some RNA
processing events occur post-transcriptionally depending on the type RNA molecule. For
example, the m7G cap of several RNAPII substrates, such as spliceosomal snRNAs and
snoRNAs, undergo additional methylation to form 2,2,7-trimethyl Guanosine (TMG), which
occurs cytoplasmically and in a few instances in the nucleus (Jády et al., 2004; Seto et al.,
1999; Webb and Zakian, 2008).
Regardless of their specific downstream function, all RNAPII transcripts must be
separated from the polymerase and DNA template and protected to avoid non-regulated
degradation. Unsurprisingly, given the diversity of RNAPII transcripts, the process of
separating the RNA transcript from the DNA template and RNAPII, as well as protecting the
3′ terminus of the RNA transcript (here referred to as 3′ end processing) is complex and
tightly regulated. The mechanism of 3’ end processing can be thought of as a two-step
event involving first cleavage of the nascent RNA followed by additional modification to
stabilize the processed transcript. The purpose of cleaving RNAPII transcripts is two-fold.
First, to release the nascent transcript from the polymerase promoting further modification
and second to promote termination of RNAPII through the action of exonucleases (such as
Xrn2) on the downstream RNA product (Rosonina et al., 2006). The 3′ terminus of the
transcripts are further modified to stabilize the transcript through the activity of polyA
polymerase (in the case of mRNA) or by exonucleases to generate a stable secondary
structure at the 3’ end (in the case of histone mRNA and non-coding RNA). The process of
3’ end processing is governed by cis elements and trans acting factors. Moreover, the
diversity of RNAPII transcripts means that the regulatory elements of 3′ end processing of
these transcripts vary tremendously (for reviews see (Legendre and Gautheret, 2003; Peart
3

et al., 2013; Tian and Graber, 2012; Wilusz and Spector, 2010)) . Below, I provide a brief
discussion on the cis elements and trans factors that govern many of the RNAPII 3’ end
processing events including coding RNA (both polyadenylated and non-polyadenylated) and
non-coding RNA (including snRNA, telomerase RNA, and long non-coding RNA).

The 3’ end formation of non-coding RNA: snRNA 3′end formation is not an integrated tail
The majority of the Uridine rich small nuclear RNAs (snRNAs) are transcribed by
RNAPII and are ~60-200 nucleotides in length (Peart et al., 2013). These snRNAs are
packaged into RNA protein complexes called small nuclear ribonucleoproteins (snRNPs)
and they facilitate splicing of pre-mRNAs or promote the 3′ end formation of replication
dependent histone mRNA. In metazoans, transcription of the snRNAs by RNAPII requires
the small nuclear activating protein complex at the promoter (Jawdekar and Henry, 2008;
Yoon et al., 1995).This is relevant because the accurate and precise 3′ end formation of the
RNAPII-transcribed snRNAs is intimately connected to promoter identity as well as the
distance between the site of termination and the promoter (Hernandez and Weiner, 1986;
Ramamurthy et al., 1996). The 3′ end formation of the snRNAs is dependent on recognition
of, not only the correct promoter, but also the 3′box downstream of the gene body and
specific phosphorylation of the CTD of RNA PII (Figure 1.1A). Together the cis regulatory
elements allow for the recruitment of a protein complex (Chen and Wagner, 2010; Peart et
al., 2013), which is responsible for cleaving the snRNA.
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Figure 1.1. snRNA 3′ end processing in humans and S. cerevisiae. (A). The 3′ end formation
of the RNAPII transcribed snRNA in humans requires a snRNA specific promoter and
conserved downstream element, the 3′ box located proximal to the end of the mature
snRNA. The snRNA promoter is recognized by the small nuclear activating protein complex
(SNAPc), and with the presence of the general transcription proteins recruits RNAPII. Along
with the RNAPII, a multi-subunit complex, Integrator, located on the CTD of the polymerase
is brought in close proximity to the nascent RNA. The snRNA is cleaved by a heterodimer of
subunits 9 and 11 of the Integrator complex. (B). S. cerevisiae does not have integrator
proteins and instead the snRNAs are either polyadenylated using the cleavage and
polyadenylation factors to cleave the RNA and add a poly (A) tail. Another pathway, involves
endonucleolytic cleavage of a stem loop structure in the pre-snRNA by the RNase, Rnt1.
Subsequently, the snRNA can be further trimmed to generate the final 3′ terminus.
Alternatively, the snRNA 3′ end formation uses the Nrd1/Nab3/Sen1 termination pathway to
cause the release of the nascent RNA from the polymerase.
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In metazoans, snRNA 3′ end formation is accomplished by a large multi-protein
complex, termed the Integrator complex (Baillat et al., 2005). The Integrator complex is
comprised of ~14 subunits, which play different but as yet unresolved roles in snRNA
transcription and termination (Baillat et al., 2005; Chen and Wagner, 2010; Chen et al.,
2012). The subunits responsible for cleaving the snRNA are Integrator subunit 9 and
Integrator subunit 11, and following the cleavage by these subunits the snRNA is released
from the DNA template (Figure 1.1A). Several of the Integrator subunits display reciprocal
dependency, in that depletion of one subunit leads to the depletion of another (Albrecht and
Wagner, 2012), however the functional relevance of this observation for snRNA 3′ end
formation is not straightforward. The RNA binding partner within the complex is unknown
resulting in a black box for how Integrator positions the RNA for cleavage; and while it is
known that the Integrator associates with the CTD of RNAPII, during snRNA transcription,
the sequence of events leading to the recruitment of the Integrator complex to facilitate
cleavage of the snRNA remains nebulous (Baillat and Wagner, 2015). However, the identity
of the protein complex, as well as the cis requirements for snRNA 3′ end formation is not
conserved between metazoans and fungi (Peart et al., 2013).
In certain fungi, such as Saccharomyces cerevisiae, the cleavage and subsequent 3′
end of the Uridine rich snRNA is accomplished through several distinct processes, which
may act as a failsafe to ensure the production of the snRNA (reviewed by (Peart et al.,
2013)). The snRNAs in S. cerevisiae are processed at the 3′ terminus utilizing
endonucleolytic cleavage, exonucleolytic trimming and tailing. One pathway, uses
endonucleolytic cleavage of S. cerevisiae snRNA by Rnt1, a double strand specific RNase
III, which cuts the stem loop of pre-snRNA to release a transcript with an unprotected 3′ OH.
This pre-snRNA is then trimmed by the exonuclease, like the RNA Exosome or Rex1.
Alternate pathways use transcription termination by means of the Nrd1/Nab3/Sen1 pathway,
or likely involve the cleavage and polyadenylation factor complex (Peart et al., 2013).
7

U2snRNA in yeast can be polyadenylated utilizing the components of the cleavage and
polyadenylation machinery, although some of the factors were dispensable for processing
(Abou Elela and Ares, 1998; Morlando et al., 2002). Still, snRNAs in S. cerevisiae also use
the polyadenylation independent Nrd1/Nab3/Sen1 pathway, which has some functional
interconnections with the cleavage and polyadenylation machinery (Porrua and Libri, 2015).
Nrd1 and Nab3 are RNA binding proteins, and Sen1 is a helicase; the three proteins can
associate with a phosphorylated RNAPII CTD, and play an important role in termination of
RNA PII transcription (Arndt and Reines, 2015). Thus, utilization of this pathway effectively
couples transcription termination with RNA 3′end formation. Despite the different complexes
required for 3′ end formation of snRNA in fungi and vertebrates, the subsequent fate of the
snRNAs is similar.

The 3’ end formation of non-coding RNA: telomerase RNA 3′end formation, means to an
end.
The telomerase RNA is transcribed by RNAPII in vertebrates and fungi and forms the
RNA component of the telomerase enzyme, which maintains the length of the telomere. The
sequence of the telomerase RNA varies, and only few of the critical secondary structure
elements are highly conserved (Rubtsova et al., 2012). Variability in the conservation of
several elements, reflects the diversity in how the RNA is processed despite the end result
from all species being the formation of the ribonucleoprotein telomerase. Like the snRNAs,
the telomerase RNA also harbors a hypermethylated m7G in Homo sapiens,
Schizosaccharomyces pombe and Saccharomyces cerevisiae (Jády et al., 2004; Seto et al.,
1999; Webb and Zakian, 2008). While significant inroads have been made in identifying and
characterizing the 3′ end formation of several RNAPII transcripts, most notably mRNA which
will be discussed later and snRNAs, this compendium of knowledge is less generalized and
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congruent for telomerase RNA. The insights that have been gathered over the past few
years for the formation of 3′ end formation of telomerase RNA (hereafter referred to as TER
for simplicity) show great diversity between fungi and vertebrates (Rubtsova et al., 2012).
In H. sapiens, and presumably other vertebrates the formation of the 3′ terminus of
TER is dependent on a highly conserved domains, CR7 and box H/ACA (Figure 1.2A)
(Mitchell et al., 1999; Theimer et al., 2007). This domain combination is a unique feature to
vertebrate TER (Chen and Greider, 2004). The H/ACA motif is a feature of a class of
snoRNAs and the 3′ end processing is likely analogous (Balakin et al., 1996; Mitchell et al.,
1999), however the precise mechanism is yet to be delineated. While heterologous
expression of the human TER in S. cerevisiae indicates that it 3′ end processing is
dependent on several protein factors that mediate processing of yeast H/ACA snRNAs (Dez
et al., 2001), the additional requirement of the CR7 domain for 3′ processing (Fu and Collins,
2003) of the human TER suggests that novel factors are in play.
In yeast, the 3′ terminus of TER is defined after the Sm binding site (Figure 1.2A)
(Gunisova et al., 2009). However, the different yeast species process the 3′ terminus
differently, two case examples, S. pombe and S. cerevisiae using will be presented.
In S. cerevisiae there are also two forms of TER, a polyadenylated and nonpolyadenylated form, the former being a minor species. The major non-polyadenylated
species ultimately forms the RNA component of the TER. Rather than being processed from
the longer polyadenylated species (Chapon et al., 1997), the non-polyadenylated TER
appears to be processed independently (Noël et al., 2012). The TER of S. cerevisiae has
multiple 3′ end processing signals, one of which is dependent on the Nrd1/Nab3 termination
pathway (Noël et al., 2012). The other appears to utilize the canonical pathway for cleaving
and polyadenylation. Polyadenylated TER production is dependent on the Cleavage Factor
and PolyA polymerase (Chapon et al., 1997), which are essential factors for cleavage and
polyadenylation of mRNA in budding yeast. This observation has created a model where the
9

polyadenylated form of TER appears to be generated from transcriptional read-through, but
what its functional role is or whether it is further processed is unclear. To create the nonpolyadenylation form of TER, it is thought that the Nrd1/Nab3 protein complex binds to a
terminator sequence in TER and facilitates termination of TER. An intriguing idea posited
suggests that presence of non-polyadenylated and polyadenylated forms of TER in several
yeast species (although the 3′ end formation process is accomplished through different
means) is a kind of precautionary measure to ensure the production of the required RNA
(Noël et al., 2012). Interestingly, this Nrd1/Nab3 dependence for TER 3′ end processing did
not show a dependency on the Sen1 helicase. This may be analogous to the some of the
functional redundancy of snRNA 3′ end processing in S. cerevisiae (Peart et al., 2013). In
both humans and S. cerevisiae the precise exonuclease that trims the mature TER or the
endonuclease which cleaves the TER from the DNA template after the cleavage site is
demarcated by the interacting protein is unclear.
Two models for the formation of mature TER are possible. Non-polyadenylated TER
and polyadenylated TER in both humans and S. cerevisiae may be differentially processed,
utilizing different endonucleases corresponding to the cis elements present. Alternatively,
the polyadenylated forms of TER may also be a precursor for the mature TER (Chapon et
al., 1997). It has led to the speculation that nuclear exosome may play a role in this process,
where, in S. cerevisiae the Sm site in the TER likely bound by Sm proteins marks the
termination site to which the exosome trims the polyadenylated precursor (Figure 1.2B) (Coy
et al., 2013).
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Figure 1.2. Yeast and Human Telomerase RNA 3′ end processing. (A). Signals required for
Telomerase 3′ end formation in humans and yeast. Efficient TER 3′ end processing in
humans requires a CR7 loop (indicated by red box) and H/ACA box, the human TER is not
polyadenylated. Yeast TER may be polyadenylated, however, mature TER incorporated into
the telomerase do not necessarily require poly(A) tails. The 3′ terminus of yeast TER share
a Sm site (posited to act as a boundary element), X indicates additional cis elements used
by different yeast genus to generate mature TER. (B). 3′ end formation of TER in S.
cerevisiae uses two distinct pathways to generate mature TER. S. cerevisiae uses
Nrd1/Nab3 termination complex to terminate transcription and release the nascent TER. The
Sm protein bound TER is protected from exonucleolytic degradation. Alternatively, the
Cleavage and Polyadenylation (CPF) proteins are recruited to cleave the nascent TER
which is subsequently polyadenylated. C. The TER in yeast of the genus
Schizosaccharomyces contain a suboptimal intron. An incomplete splicing reaction,
dependent modulated by stringency of snRNP binding to the splice regulators, 5′ or 3′ splice
site (SS) and branch point (BP). The Sm binding site, bound by Sm proteins, is also required
for the generation of mature TER. The first transesterification reaction of splicing is
completed, by exon ligation is suppressed and the 3′ exon and lariat are discarded. The Sm
proteins (white circles) promote the trimethylation of the m7G cap of the TER, and then are
replaced by the Lsm proteins (yellow circles).
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Like in S. cerevisiae, the mature TER of S. pombe that forms a subunit of telomerase
is the non-polyadenylated form, however in S. pombe, the 3′ end formation of TER uses the
spliceosome, to cleave the mature TER from the polyadenylated precursor (Figure 1.2C)
(Box et al., 2008). The spliceosome is a large ribonucleoprotein complex that typically
removes introns from pre-mRNAs, by catalyzing transesterification reactions, which excise
an intron, and ligate the flanking exons (Matera and Wang, 2014; Smith et al., 2008). An
analysis of the polyadenylated TER in S. pombe revealed that a small portion had an
internal deletion of 56 nucleotides, closer analysis of this deletion revealed that the TER
contained an intron. Intriguingly, removal of this intron or substituting a heterologous
efficiently spliced intron resulted in a decrease in the mature form TER (Box et al., 2008).
The 5′ splice site is recognized by the U1snRNP (Box et al., 2008) which is the first step of
canonical splicing reactions in eukaryotes (Smith et al., 2008). However, in contrast to the
canonical splicing reactions with two transesterification, completion of only the first
transesterification reaction is required for generation of mature TER (Box et al., 2008).The 5′
splice site in TER overlaps with the Sm binding site and it was subsequently demonstrated
that Sm protein binding is critical for spliceosomal cleavage (Tang et al., 2012) and thus Sm
protein binding may impair the second transesterification reaction. Subsequent to the
spliceosomal cleavage, the Sm proteins are replaced by Lsm proteins which stabilize the
mature TER (Tang et al., 2012). Spliceosomal cleavage is conserved in yeast of the genus
Schizosaccharomyces (Kannan et al., 2015) and possibly in other yeast as splice sites were
detected in TER genes in several yeast of the genus Candida (Gunisova et al., 2009). A
significant contribution to impairment of the complete splicing reaction in the TER is a
distortion of the kinetics of splicing due to the suboptimality of the intron ((Kannan et al.,
2013, 2015) and reviewed (Peart et al., 2013)).
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The 3’ end formation of non-coding RNA: A NEAT trick
The nuclear enriched abundant transcripts, NEAT1 and NEAT2 are mammalian
conserved polyadenylated long non-coding RNA (lncRNA) (Hutchinson et al., 2007). NEAT1
is a structural lncRNA essential for paraspeckles in the nucleus of mammalian cells
(Sunwoo et al., 2009). Paraspeckles are subnuclear compartments suggested to control
gene expression by retaining certain RNA molecules in the nucleus. They may also serve as
marker for loss of pluripotency (reviewed by (Bond and Fox, 2009; Yamazaki and Hirose,
2015)). NEAT2, also known as MALAT1 for metastasis-associated lung adenocarcinoma
transcript 1, is a long lived lncRNA that is frequently associated with several cancers, and
plays inconclusive roles in modulating mRNA splicing and influencing gene activation
(Gutschner et al., 2013). Both NEAT1 and NEAT2 are polyadenylated, however, they also
undergo additional processing to generate a triple helical structure at the 3′ terminus which
is essential for stabilization ((Brown et al., 2012; Wilusz et al., 2012). NEAT1 is transcribed
as two isoforms Menε (a polyadenylated ~3.2kb lncRNA) and Menβ (a non-polyadenylated
~23kb lncRNA), while NEAT2 is processed to generate the nuclear retained MALAT1 and a
cytoplasmic short-lived mascRNA (Wilusz et al., 2008, 2012). Menβ and Malat1 do not have
canonical polyadenosine tails, instead they have an encoded run of adenosines at the 3′
ends (cleavage of the RNA occurs after the run of encoded adenosines). The polyadenosine
tails at the 3′ ends are both short, however, the transcripts are surprising stable (Sunwoo et
al., 2009; Wilusz et al., 2008). The presence of adenosine stretch in the template DNA and
the lack of signals for cleavage and polyadenylation near the 3′ ends revealed a novel
method of processing the 3′ ends of an RNAPII transcript. Illumination of this process was
possible due to presence of small non-coding RNA, mascRNA. The mascRNA structurally
resembles a transfer RNA as it is predicted to adopt a cloverleaf fold and has a CCA
modification at the 3′ end. The 5′ end of mascRNA corresponds to the 3′ end of the Malat1
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lncRNA, and production of mascRNA was dependent on Malat1 production. This led to the
speculation, which was proven, that the 3′ ends of the Malat1 lncRNA is processed by
endoribonuclease, RNase P (Wilusz et al., 2008). RNase P cleaves Malat1 and Menε/β
downstream after the encoded adenosine stretch to generate an lncRNA with a short tail,
upstream of the tRNA like fold. The downstream product of the cleavage in the case of
mascRNA is further processed at its 3′ terminus by RNase Z, prior to the addition of the
CCA (Figure 1.3). It remains unclear if the process occurs co-transcriptionally or post
transcriptionally (that is, if the process occurs prior to a canonical cleavage and
polyadenylation event or on an already cleaved and polyadenylated transcript) (Sunwoo et
al., 2009; Wilusz et al., 2008).
The stability of Menε/β and Malat1 given their short adenosine tails was surprising.
Located near the 3′ end of the Menε/β and Malat1 RNA there is a conserved A and U rich
tract similar to an element called the expression and nuclear retention element (ENE) found
in the stable nuclear retained polyadenylated RNAs from Kaposi's sarcoma-associated
herpesvirus (Brown et al., 2012). It was further demonstrated by two independent groups
that the RNA adopts a triple helical fold due to the presence of the U/A rich motif (Brown et
al., 2012; Wilusz et al., 2012).
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Figure 1.3. 3′ end processing of NEAT lncRNA transcripts. The precursor NEAT lncRNA
may be polyadenylated. The mature NEAT is generated following cleavage by the
endonuclease RNase P between an A/U rich region and a clover like structure. Cleavage
generates a small tRNA-like RNA, which is further processed at its 3′ end by RNase Z, and
stabilized by the addition of a CCA tail by the CCA adding enzyme. The upstream cleavage
product is stabilized due to the formation of triple helix structure in the RNA because of the
A/U rich stretches near the 3′ terminus. Triple helix bonds are Hoogsteen (broken lines
between A/U blocks) and Watson crick (solid lines between A/U blocks).
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The 3’ end formation of Coding RNA: To cleave and polyadenylate
Coding mRNA can be broken down into two categories: those that contain a long
adenylated 3’ tail and those that lack this feature. In contrast to the majority of mRNAs that
are polyA tailed, the 3′ end of mature replication dependent histone mRNA is not
polyadenylated, rather polyadenylated histone mRNA is aberrant and thought to be
produced by inefficient 3’ end formation. Remarkably, the process of accomplishing this task
is highly complex and tightly regulated. The core machinery responsible for 3′ end formation
of the coding RNAPII transcripts are the cleavage and polyadenylation specificity factors
(CPSF).
In the simplest instance, the cleavage and polyadenylation (CPA) is dependent on
the recognition of several cis regulatory elements – a polyadenylation signal (PAS), a
cleavage site (CS), an upstream sequence element (USE), and a downstream sequence
element (DSE). These cis elements are recognized and bound by the CPSF complex, the
cleavage stimulation factor complex (CstF) and the cleavage factor complex (CF). The PAS
is typically AAUAAA, and the DSE is typically U/GU rich in metazoans (Figure 1.4A).
However, this general and simple assumption of cis element organization seems to be quite
rare in mammals (Tian and Graber, 2012). Many mRNAs do not utilize AAUAAA as the
PAS, or possess a readily identifiable DSE, or USE, and a few even lack these elements
altogether. To add a further level of complexity, several mRNAs possess multiple PASs
(Beaudoing et al., 2000; Tian et al., 2005), so the process of selecting a cleavage site must
be and is highly regulated. I discuss some of the implications, and processes here.
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Figure 1.4. The 3′ end processing of mRNA in yeast and humans, and human replication
dependent histone mRNA. (A) cis regulatory elements for (i) polyadenylated mRNA in
humans (ii) polyadenylated mRNA in yeast, and (iii) non-polyadenylated histone mRNA in
humans. Canonical elements for polyadenylation of mRNA in humans are an upstream
sequence element (USE), a polyadenylation signal (PAS) a cleavage site (CS) and a U-rich
downstream sequence element. The elements for CPA in yeast are a U-rich efficiency
element (EE), an A rich positioning element (PE) and a cleavage site. The cis elements for
3′ end formation of the replication dependent histone mRNA in humans are structural and
sequence specific. First is the requirement for a stem loop and second is the requirement for
histone downstream element (HDE). (B) The cis elements of mRNA 3′ end formation are
recognized by several trans acting factors. Shown are some of the proteins that are shared
by all three mRNA processing events. (i) and (iii) human mRNA 3′ end processing both use
the CPSF proteins 73 and 100 for cleavage supported by the scaffold protein Symplekin. In
yeast (ii) the orthologues of these proteins Ysh1, Ydh1 and Pta, respectively, facilitated the
cleavage of the mRNA. In yeast the PE is recognized and bound by RNA-15, an orthologue
of human CstF64 that binds the DSE in the human pre-mRNA transcript. The PAS in
humans is bound by WDR33. (iii). In the replication dependent histone mRNA, the HDE
base pairs with the U7 snRNP, and the stem loop binding protein (SLBP) binds the histone
stem together recruiting the CPSF proteins.
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CPA is reliant on several cis elements, key is the hexameric PAS; but how is the
hexamer, for example AAUAAA, functionally characterized as a signal for polyadenylation?
There is typically an enrichment of uridines in the immediate vicinity of an identifiable
hexanucleotide PAS (Legendre and Gautheret, 2003). In addition, the site of cleavage and
subsequent tailing is biased toward CA or UA dinucleotide (Derti et al., 2012; Li and Du,
2013; Sheets et al., 1990). The complex of proteins regulating CPA was initially purified in
the late 20th century through a series of biochemical purifications and additional proteins
have since been shown to play a role in this process (reviewed and references within (Shi
and Manley, 2015; Xiang et al., 2014)). The Uridine stretches in the RNA are bound by the
CF and CstF complexes, while the hexamer PAS, in the case of AAUAAA, is bound by the
CPSF protein WDR33 (Figure 1.3B) (Chan et al., 2014; Schönemann et al., 2014). The
mRNA is then cleaved by the endonuclease CPSF73 (Dominski, 2010; Mandel et al., 2006),
which forms a stable core with CPSF100 and Symplekin ((Xiang et al., 2014). Although
there are differences in the stringency of requirement for certain elements or factors
depending on the context of the gene expression, these factors work together to facilitate
efficient cleavage and polyadenylation the mRNA.
The trans acting factors required for cleavage and polyadenylation are highly
conserved across fungi and metazoans (Tian and Graber, 2012; Xiang et al., 2014; Yang
and Doublié, 2011). In S. cerevisiae the cis regulatory elements which mediate cleavage
and polyadenylation are less defined, but no less critical for CPA. The elements required
and sufficient for CPA in S. cerevisiae are an efficiency element, a positioning element, a
cleavage site, and an enrichment of uridines around the cleavage site (Figure 1.2A) (Guo
and Sherman, 1996; Tian and Graber, 2012). While several of the protein machinery are
similar, there are differences in the binding specificities which likely reflect the differences in
how sites of polyadenylation are determined in metazoans compared to fungi. For example,
the A-rich positioning element in yeast which is analogous to the mammalian
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polyadenylation signal is recognized by a homologue of the human CstF protein 64. In
humans, CstF64 is found downstream of the site of polyadenylation at the U/GU rich DSE
(Figure 1.2B). However, both human and yeast cis elements for CPA are enriched for
uridines (reviewed in (Tian and Graber, 2012; Xiang et al., 2014)).
The process known as alternative cleavage and polyadenylation (APA) describes
how one gene uses two or more different PAS, without necessarily changing the coding
region to generate different mRNAs. Regulation of polyadenylation site affects the length of
the 3′ untranslated region (UTR), thus can affect mRNA behavior. As a consequence of
APA, mRNA localization, stability and translatability can be changed (Mayr, 2016). These
changes can have drastic effects contributing to disease pathologies (Ogorodnikov et al.,
2016), nonetheless, APA is not an aberrant occurrence in the cell. Rather, cell type can
affect the APA, for example the mRNAs in the brain tend to have longer UTRs, utilizing more
distal PAS compared to other cells (Mayr, 2016). Regulation of APA utilizes multiple trans
acting factors, many of which are part of the core CPA machinery. The mechanisms and
signaling cascades that affect the choice of polyadenylation site are still being unveiled,
which contributes to understanding of general gene expression regulation, but also
introduces new therapeutic targets (Klerk et al., 2012; Masamha et al., 2014, 2016).

The 3’ end formation of Coding RNA : To cleave and not polyadenylate
Similar to the other mRNAs in metazoans, the replication dependent histone mRNA
depends on the CPSF machinery to remove the nascent RNA from the DNA template.
However, of this large multiprotein complex, only a subset of proteins is required.
Specifically, the cleavage factor including CPSF73 and 100 and the scaffold Symplekin. As
mentioned previously, in higher metazoans such as humans, the histone mRNA is not
polyadenylated; in its place, a stable stem loop at the 3′ terminus protects the transcript from
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decay. In addition to CPSF73 and CPSF100, which cleave the transcript, histone mRNA 3′
end formation also requires the U7 snRNP and stem loop binding protein (SLBP). The U7
snRNP and SLBP recognize the cis regulatory elements of the histone gene including a
histone downstream element (HDE) and stem loop respectively (Figure 1.3A/B) (Dominski
and Marzluff, 2007; Marzluff et al., 2008). Additional trans acting factor facilitate the
recruitment of the CPSF machinery and distinguishes histone mRNA 3′ end formation from
the canonical mRNA cleavage and polyadenylation (reviewed (Dominski and Marzluff, 2007;
Köhn and Hüttelmaier, 2016; Marzluff et al., 2008; Romeo and Schümperli, 2016)).

Significance: All’s well that ends well.
The nuclear processing of the 3′ end of RNAPII transcripts affects their localization,
(whether they are exported, retained or decayed). The 3′ end of the RNAPII transcript is
subject to regulation to control transcript fate, affecting the behavior and stability. For
example, polyadenylated mRNAs are exported to the cytoplasm and once there, removal or
shortening of this protective features at the 3′ terminus subjects the mRNA to decay, impairs
translation of the mRNA into protein, or can lead to sequestration of the mRNA (Weill et al.,
2012).
As there are many distinct types of RNAPII transcripts, regulation of the process by
which the 3′ ends of the transcripts are formed, is critical because it dictates the behavior of
the RNA. The redundancies within the pathway, the fail-safes and stopgaps present,
demonstrate that appropriate 3′ end formation of the transcript is critical for cell
homeostasis. The implications of dysregulated RNA 3’ end processing is evident in several
diseases, dyskeratosis congenita, muscular dystrophy, cancer amongst others (Chen and
Greider, 2004; Danckwardt et al., 2008; Ogorodnikov et al., 2016). However, not only is the
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understanding of the 3′ end formation of RNA important for understanding disease etiology
and designing strategies for intervention, but also to contribute to the body of science which
governs how we understand how we work. The 3′ end formation of RNA can serve as a
signal for the termination of transcription for RNAPII, which is important given the myriad of
RNAPII transcripts so that the genome of increasingly complex organisms can be partitioned
(Kuehner et al., 2011).
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Chapter 2 : Introduction to Facioscapulohumeral Dystrophy
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Overview of Facioscapulohumeral Dystrophy
Facioscapulohumeral dystrophy (FSHD) is a progressive debilitating muscle
disorder. The prevalence of FSHD varies according to the population surveyed; however,
since the use of genetic testing the average prevalence is approximately 6.4 per 100000
persons, with the highest incidence and prevalence to date reported in the Dutch population
(Deenen et al., 2014). FSHD was first characterized in late 1800s but the molecular
mechanism was not realized until the 1990s when the disease was associated with the
reduction in D4Z4 microsatellite repeats on chromosome 4 below a threshold number of 10
(healthy individuals contain 10-100 D4Z4 repeats) (van Deutekom et al., 1993; Wijmenga et
al., 1992). However, it was not until the last decade that significant inroads have been made
in delineating the molecular etiology of the disease (Lemmers et al., 2010a, 2012; Snider et
al., 2010).

Clinical Features
The clinical features of FSHD are highly heterogeneous, and range from mild to
severe. Severe FSHD may lead to wheelchair dependency, and may involve mental
retardation (Tawil and Van Der Maarel, 2006). However, more often individuals with FSHD
may present with hearing loss and retinal telangiectasia, the latter occasionally progressing
to Coats Disease (Tawil and Van Der Maarel, 2006). Disease severity has been correlated
with age, where severe cases of FSHD referred to as infantile onset FSHD lead to
progressive muscle strength degeneration and other organ functional diminution. The
relative severity of the disease is also often associated with the size of the D4Z4
contractions, with smaller fragments, 1-3 repeats, associated with severe cases (Tawil and
Van Der Maarel, 2006). Interestingly, one recent study showed that the severe cases of
FSHD associated with smaller D4Z4 fragments were more often observed in patients that
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had de novo FSHD, which arise without a previous family history of the disease (Nikolic et
al., 2016). FSHD patients, in most cases display asymmetric muscle weakness, and facial
drooping. FSHD is a rare muscular dystrophy that does not present cardiac involvement,
although, there are case studies of FSHD patients presenting with epilepsy(Chen et al.,
2013b; Funakoshi et al., 1998; Saito et al., 2007). One of the more prevailing features of
FSHD is chronic pain and fatigue (further reading for clinical features of FSHD (Mul et al.,
2016; Tawil and Van Der Maarel, 2006; Tawil et al., 2015)). As a consequence of the high
clinical variability and the occasionally subtle phenotypes the incidence and prevalence of
FSHD is posited to be underestimated (Deenen et al., 2014).

Molecular Features

FSHD is primarily an autosomal dominant disorder, however there is a high
incidence of de novo mutations engendering disease (Sacconi et al., 2015; Tawil et al.,
2014). FSHD is mainly associated with contractions of the D4Z4 repeats on subtelomeric
region of chromosome 4 (van Deutekom et al., 1993; Wijmenga et al., 1992). In spite of the
similarities of the q arm of chromosomes 4 and 10 (over 98%) (van Geel et al., 2002), early
characterization of the FSHD exclusively linked the disease to chromosome 4q, in particular
the 4qA allele (de Greef et al., 2009; Lemmers et al., 2004, 2007; van Overveld et al., 2003;
Wang et al., 2011). A single D4Z4 repeat is 3.2 kb in length and is thought to contain a
single promoter and open reading frame encoding Dux4 (see below) but the lack of a
cleavage and polyadenylation signal within the repeat prevents production of a Dux4 mRNA.
Approximately 95% of the cases of FSHD have contracted D4Z4 alleles (Statland
and Tawil, 2014), However, patients have been clinically diagnosed with FSHD and bear no
contractions of the D4Z4 repeats. Instead, these patients, classified as FSHD2, have
reduced repressive methylation marks on their D4Z4 repeats thereby de-repressing this
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genomic region similar to what is observed to occur as a consequence of D4Z4 contraction
in FSHD1 (van der Maarel et al., 2012; Statland and Tawil, 2014). Concomitant with the
repression of the D4Z4 repeats, FSHD is predicated by single nucleotide polymorphisms
(SNP) present within the region flanking the D4Z4 repeat on telomeric side that is specific to
the 4qA allele (Lemmers et al., 2007, 2010a). The 4qA allele is distinguished, from the 4qB
or 4qC allele, because of the presence of a truncated terminal D4Z4 repeat, pLAM, and βsatellite repeat region (Lemmers et al., 2007, 2010b). The 4qA and 4qB alleles are the most
predominant within the population, within which the most common haplotypes are A161,
A166 B163, and B168 (Lemmers et al., 2010b); however, only the 4qA161 haplotype is
associated with FSHD, as it contains a SNP that generate a non-consensus polyadenylation
signal (PAS), AUUAAA, in the pLAM region (Lemmers et al., 2010a). The PAS allows for
productive transcription of the Dux4 gene from the terminal D4Z4 repeat (Figure 2.1).
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Figure 2.1. Schematic of the D4Z4 Repeats and the FSHD Locus. (A) Chromosome
alignment of showing similarity between 4qA, 4qB and 10qA, with only the 4qA allele being
associated with FSHD, with 4qB lacking pLAM and β-satellite sequences. D4Z4 repeats
represented by gray overlapping triangles representing repressed state, with repeats
numbering >10, pLAM and β-satellite are indicated by red and white boxes respectively. (B)
Specific haplotype of FSHD afflicted individual. Transcriptional derepression as a
consequence of reduction in number of D4Z4 repeats to 1-10, or mutation in modifier
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proteins. The 4qA161 haplotype, contains a SNP generating non-consensus PAS,
AUUAAA. The presence of the PAS allows for productive transcription
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There is evident, incomplete penetrance of the disease associated with both the SNP
generating a non-consensus PAS and the contraction of the D4Z4 repeats (Scionti et al.,
2012). For example, there are individuals who display reduction in the number of D4Z4
repeats or hypomethylation of the D4Z4 repeats in the presence of the permissive haplotype
who are asymptomatic (Lemmers et al., 2012; Scionti et al., 2012) Moreover, although there
is a general correlation between repeat length with disease severity, this is not absolute
(Nikolic et al., 2016; Sacconi et al., 2013; Scionti et al., 2012). These observations support
the hypothesis that genetic modifiers exist that can affect the D4Z4 locus in trans. An
example of such a modifier is the gene SMCHD1 (structural maintenance of chromosomes
flexible hinge domain containing 1). Individuals with FSHD2 can have the epigenetic state of
their D4Z4 repeat maintained in the hypomethylated state due to haploinsuffiency of
SMCHD1 (Lemmers et al., 2012). Recently, heterozygous mutations in DNA
methyltransferase 3B (DNMT3B) were reported to also derepress the D4Z4 repeats; and are
posited to contribute to FSHD2 in the absence of SMCHD1 mutations (van den Boogaard et
al., 2016). Intriguingly, the disease displays a strong reliance of the epigenetic state of the
D4Z4 repeats, with one group reporting that mutations in the SMCDH1 ‘modified’ the FSHD
disease severity when coupled with contracted D4Z4 repeats (Sacconi et al., 2013).

Model System for FSHD Investigation
Currently there is no established animal model for FSHD, although, several animals
have been generated to study aspects of FSHD (Jones et al., 2016; Lek et al., 2015). The
majority of the shortcomings of the various animal models may be related to the degree of
divergence seen between D4Z4 repeats in ape primate and other mammals. Indeed,
transgenic mice animals containing the D4Z4 repeats fail to completely recapitulate the
disease (Krom et al., 2013). Several candidate genes located in the vicinity of the D4Z4
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repeat region have been used to generate animal models of FSHD (Dandapat et al., 2014,
2016; Gabellini et al., 2006; Jones et al., 2016; Mitsuhashi et al., 2012). For example, one of
the longstanding candidate genes of FSHD, FRG1, has been used to generate mice that
presents some of the features of the disease (Gabellini et al., 2006), however, this required
high overexpression of the gene. The level of FRG1 overexpression in FSHD patients is
correlatively but not definitively related to the D4Z4 repeat length, and thus the phenotype in
the mouse may not be directly related to FSHD. In addition the reproducibility of FRG1
expression in biomarker assays for FSHD is low (Osborne et al., 2007; Rahimov et al.,
2012). The variability, sensitivity and, or subtlety of phenotypes in animal models generated
for FSHD, underscores the complexity of the disease. The lineage specificity of the D4Z4
repeats, the subtelomeric location of the FSHD locus, the variable expression of several
candidate genes (gene present within the D4Z4 repeats – Dux4, or adjacent to the D4Z4
repeats – ANT1, FRG1, and FRG2) as well as the epigenetics all contribute to making the
development of an animal model for FSHD technically challenging.

Dux4: Leading Candidate Gene of FSHD
Double Homeobox 4, Dux4, has emerged as the leading candidate gene of FSHD
and is the singular, highly conserved open reading frame located in the D4Z4 repeats.
Previously, stated to be primate specific, it has been shown that the D4Z4 repeats are found
in several placental mammals, however, the topology of the 3.3kb D4Z4 repeat with the
Dux4 ORF (with two homeodomains and an activation domain) is nearly perfectly aligned in
higher primates, humans, chimpanzees and orangutans (Clapp et al., 2007; Giussani et al.,
2012). Despite the high degree of ORF conservation of the Dux4 gene (Clapp et al., 2007),
the precise biological role of Dux4 is unclear. Dux4 protein can be detected in muscle
biopsies of fetuses with FSHD and the Dux4 mRNA can be detected in the patients with
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FSHD but is not typically found in somatic cells of healthy individuals (Ferreboeuf et al.,
2014; Snider et al., 2010). Recent studies employing overexpression of Dux4 in mouse
derived myoblasts do not replicate the transcriptome changes of Dux4 expression in human
cell lines (Sharma et al., 2013); and in FSHD mice models that feature Dux4 expression only
~22% of the genes differentially regulated overlap with human genes (Krom et al., 2013).
This is likely due to the Dux4 targets not being present in mice, as Dux4 mainly binds to
retroelements and LTR regions (Sharma et al., 2013). Nonetheless, transgenic mice bearing
randomly integrated D4Z4 repeats, show a human-like epigenetic topology, in that the locus
is typically epigenetically silenced and shortened repeats bear less repressive features,
marked with reduced CpG methylation and reduced ratio of H3K9me3:H3K4me2 (Krom et
al., 2013). So, while the ORF (in particular the homeodomain) is conserved, suggesting a
protein coding function, its presence in the likewise conserved D4Z4 repeats, suggests that
the expression of Dux4 is subject to a high degree of epigenetic regulation.
Animal models using Dux4 expression as a driver for pathogenesis have replicated
aspects of FSHD pathology but not the full scale of the disease (Lek et al., 2015) (Lek et al.,
2015). One mouse model, integrating the Dux4 gene on the X chromosome, showed that
the presence of the gene led to increased male lethality and the X chromosome bearing the
gene was preferentially silenced in female offspring. Although, there was not observed
significant muscle weakness, retinal abnormalities were reported in surviving mice
(Dandapat et al., 2014). The retinal abnormalities were also reported in another mouse
model (Krom et al., 2013). However, likely due to a dissimilarity in the transcriptome of Dux4
in mice versus humans (Sharma et al., 2013), none of the mouse models fully recapitulate
the disease. An alternative approach utilized xenograft models, in which skeletal muscle
tissue from FSHD patients is engrafted into mice to reproduce the Dux4 expression profile
(Zhang et al., 2014). However, this model is more suited to assaying molecular outcomes
due to the presence of the human tissue and localized repair of the xenograft muscle, but,
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will not be sufficient for functional studies, such as grip strength which assesses the muscle
strength of the mouse. In zebrafish, the ectopic expression of Dux4 led to severe skeletal
malformations, which could be rescued by morpholinos reducing Dux4 (Mitsuhashi et al.,
2012). In human cell lines it has been shown that Dux4 inhibits myogenesis – differentiation
of myoblast to myotubes (Bosnakovski et al., 2008). However, FSHD patients present no
difference in the apparent myogenesis and Dux4 expression appears to be enhanced by
myogenesis (Block et al., 2013; Tsumagari et al., 2011). Collectively, the efforts to
recapitulate aspects of FSHD using Dux4 have been accomplished with mixed success
further reflecting the complexity of the disease.

RNA Processing in FSHD
The Dux4 ORF is located entirely in the first exon of the gene, while the 3′
untranslated region (UTR) has two introns. In the testis, where Dux4 is found to be
expressed in healthy individuals, an alternatively spliced UTR results in usage of a
polyadenylation signal in a distant downstream exon, exon 7 (Figure 2.2A). This distal PAS
appears to be not active in normal somatic cells and, typically only in the case of FSHD is
the Dux4 transcript expressed using a polyadenylation signal AUUAAA found due to a SNP
in Exon 3 on chromosome 4, exclusively (Snider et al., 2010). Alternative splicing of Dux4,
reportedly generates several isoforms of Dux4 (Figure 2.2 B), including a non-pathogenic
Dux4 isoform, called Dux4-s. This splice isoform, is generated from a cryptic splice site in
the Dux4 ORF in the first exon, and retains the homeodomain, but does not have the
activation domain. The pathogenic Dux4 isoforms, collectively referred to as Dux4-fl retain
the entire ORF of Dux4 containing two homeodomains and an activation domain (Snider et
al., 2010). There are two annotated RefSeq isoforms of the Dux4 transcript in Genbank:
(NM_001306068.1) and variant 2 (NM_001293798.1) that differ due to intron retention in
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variant 1 (Figure 2.2 B). The implication of the intron retention will be discussed later in this
study, however, it is likely that splicing of the Dux4 mRNA itself is highly regulated. The
expression of Dux4 mRNA is low and the full length mRNA is barely detectable (reviewed
(Richards et al., 2012)). This could be due to inefficient cleavage and polyadenylation at the
non-consensus PAS, rapid mRNA turnover or weak promoter, or due to the epigenetic
modifications at the locus. Detection of Dux4 is technically challenging, requiring a high
cycle number (typically 50 cycles) nested amplification by PCR.
One possible explanation for the low abundance of Dux4 is that it undergoes splicing
downstream of a stop codon. Moreover, the exons are short which lead to the hypothesis
that Dux4 mRNA is subject to non-sense mediated decay (NMD) (Feng et al., 2015). Feng
and company demonstrated using a mini-gene reporter system that the second intron of
Dux4 makes the mRNA susceptible to NMD, and thus results in its decay. It is likely that
both variants of Dux4 are NMD targets. The detection of the Dux4-s in patient cells and
healthy cells, as well as numerous small transcripts from the D4Z4 repeats of patient cells
(Snider et al., 2009) do not support the hypothesis that there is a weak promoter in the D4Z4
repeat. Several studies have shown that there are many different RNA transcripts generated
from the D4Z4 repeats (Snider et al., 2009), and while some of these transcripts may aid in
increasing overall transcription activity (Cabianca et al., 2012) from the D4Z4 repeats, some
have inhibitory effects (Lim et al., 2015). Significant efforts have been devoted to understand
the epigenetic regulation of the D4Z4 repeats, as this may contribute to the poor expression
of the Dux4. While the locus shows decreased repressive DNA and histone methylation
(Hewitt, 2015), it is still unclear if this contributes to Dux4 inefficient expression. Besides,
the identification of the non-consensus PAS in the Dux4 transcripts from patient cells
(Lemmers et al., 2010a), and a myriad of studies which amplify the polyadenylated Dux4,
not much work has been done characterizing the 3′ end processing of the Dux4 transcript.
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In this thesis work, I explore the 3′ processing of Dux4 to determine whether inefficient
cleavage and polyadenylation contributes to poor Dux4 expression.
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Figure 2.2 Schematic of Dux4 transcripts. (A) Grey triangle represents terminal D4Z4 repeat,
grey trapezoid repeats truncated D4Z4 repeat. Exons indicated by white rectangles, hatched
diagonal line indicate the degenerate β-satellite repeats and the red square indicates
telomeric portion of the chromosome. The Dux4 transcripts are shown indicating the exons
detected from germline and somatic cells. Somatic tissue solely produces transcripts with
using PAS with exon 3. (B) Dux4 ORF located in exon 1, contains two homeodomains,
shown as yellow rectangle, and an activation domain shown as a brown square. Alternative
splicing produces three isoforms containing exon 3, Dux4-fl variant 2, is spliced to contain
exons 1-3 consecutively (splice pattern 1). Dux4-fl variant 1 retains the first intron (splice
pattern 2). Dux4-s, a short isoform produced using a cryptic splice site in the Dux4 ORF,
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Dux4-s lacks the activation domain, and can use a stop codon present in exon 2 (splice
pattern 3). Start and stop codons are indicated by green and red circles, respectively.
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The Dux4-regulated transcriptome
As mentioned, Dux4 contains two homeodomains and an activation domain, and
belongs to the family Homeobox proteins, which are typically transcription factors.
Consistent with this idea, Dux4 can potently activate transcription at it target genes and
preferentially binds and transcriptionally activates mutlimeric copies of TAATCTAATCA
(Choi et al., 2016; Geng et al., 2012; Young et al., 2013; Zhang et al., 2016). The potent
transcriptional activation capacity of Dux4 is also evident in its role in a subset of
undifferentiated small round cell sarcomas, in which a translocation event fuses the
activation domain in the C-terminus of Dux4 to the CIC (human homologue of the drosophila
Capicua transcriptional repressor) gene and enhances its transcriptional activity; in addition,
the fusion gene can transform NIH/3T3 cells (reviewed by (Antonescu, 2014; Haidar et al.,
2015)).
Despite this clear activity, the precise biological role of Dux4 is unknown.
Overexpression has been shown to be toxic to a variety of cell lines (Block et al., 2013;
Bosnakovski et al., 2008; Wallace et al., 2011; Wuebbles et al., 2010) but its presence in
germline tissue (Snider et al., 2010) suggests a role in organismal development. Supporting
this idea, Dux4 has been shown to activate genes that are typically involved in germline
development (Geng et al., 2012). Interestingly, ChIP-Seq data from Dux4 transduced cells
shows peaks over the entire body of genes targeted by Dux4, in addition many of the Dux4
binding sites were found within intergenic regions. Further expounding on this observation, it
was shown that Dux4 binding was enriched at repetitive elements, such as mammalian
apparent long terminal repeat retrotransposons (MaLR) (Geng et al., 2012; Young et al.,
2013). The implication of this was that several of these elements became activated as
promoters driving the expression of somatically silenced transcripts. While many of the
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transcripts detected in Dux4 transduced lines were also found in the testes, the biological
role of these changes remains elusive and speculative.
Gene ontology and pathway analyses of Dux4 regulated gene expression changes
have been carried out and have shed some light on how Dux4 expression may affect
cellular behavior (Bosnakovski et al., 2008; Feng et al., 2015; Geng et al., 2012; Rickard et
al., 2015; Young et al., 2013). Using the data generated from genome wide analysis of
transcriptome changes, Feng et al reported that there was an increase in the population of
mRNA that is predicted to be subject to NMD. The mechanism for this observation is that
Dux4 is thought to cause a modest reduction in the NMD regulator UPF1. This report is
particularly intriguing because given that Dux4 is regulated by NMD, due to the presence of
its second intron, the authors posit a positive feedback loop in which Dux4 may modulate
NMD and consequently modulate itself. However, the exact mechanism through which Dux4
regulates NMD remains to be verified. In particular they do not see an overall decrease in a
NMD genes, and only show a modest change in UPF1 protein itself. However, others have
shown that Dux4 overexpression does lead to changes in relative abundance of splicing
proteins (Geng et al 2012). Intriguingly one may speculate that dysregulation of NMD may
account for some of the splicing changes observed in patient cells. However, there is likely
more at play, consequently it is imperative to understand the splicing dysfunction in FSHD
populations compared to control populations.
Toward the goal of further understanding transcriptome changes in FSHD patient
cells caused by Dux4 expression, Rickard and colleagues use a Dux4 responsive reporter to
enrich for FSHD cells that express Dux4 (Rickard et al., 2015).They and others (Snider et
al., 2010; Tassin et al., 2012) show asynchronous expression of Dux4, and demonstrate a
diffusion gradient of Dux4 within the syncytia. The asynchronous Dux4 expression, may
suggest circadian regulation wherein the gene oscillates between high and low expression,
however this has not been tested. Using Dux4 positive cells identified by sorting of reporter
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positive cells, a population of cells that would have a transcriptome representative of Dux4
action was enriched (Rickard et al., 2015). It was found that ~20% of the transcriptome is
directly changed as a consequence of expression of Dux4. Pathway analysis of the RNAseq data suggest that one the major pathways affected is RNA metabolism – in particular
splicing, surveillance and export. The dysregulation in RNA metabolism is thought to occur
through up-regulation of several proteins that belong to either mRNA splicing, surveillance
and export pathways. Interestingly amongst these genes are splicing factors SRSF2,
STAU1, DDX39B which either skip an exon or retain an intron within their own mRNA
transcripts. It must be noted that others have observed that culture conditions likely also
affect the degree of Dux4 expression (Block et al., 2013; Pandey et al., 2015) thus the
impact of Dux4 on the transcriptome may also be connected to the microenvironment.
To resolve the paradigm of how a low abundance protein like Dux4 that may be
expressed asynchronously can have meaningful impact on the transcriptome, a model has
been put forward where expression in one nucleus is sufficient to trigger activation of Dux4
target genes in a temporal and spatial manner within the syncytia. The model here posits
that Dux4 is stochastically expressed, and it may activate genes in “sentinel” nuclei, or may
diffuse across the syncytia and activate genes in other nuclei. Stochastic expression or
pulsed expression from sentinel nuclei is typical of myotubes (Newlands et al., 1998). To
date, there has been no in-depth study on the half-life of the Dux4 protein, although it is
predicted to be unstable and decayed by the proteasome (Tassin et al., 2012). It had
previously been demonstrated, in a model interrogating Dux4 expression with respect to
telomere shortening (which serves as a proxy for aging due to aging related onset of FSHD
symptoms) there is likely 1 in 2000 nuclei expressing Dux4. Upon telomere shortening, this
number significantly increased to 1 in 200 nuclei (Stadler et al., 2013). Dux4 mRNA
transcribed in one nucleus is exported to the cytoplasm where it is translated and returns to
the nuclei closest to its translation site, but it may also diffuse within the syncytia and
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activate transcription in distal nuclei. However, the length of time and the distance it diffuses
is dependent upon its stability and the proximity of nuclei, thus a careful determination of
Dux4 protein stability is necessary to develop this model further.
But questions still remain, what is the permissive amount of Dux4 protein before it
becomes toxic to the cells? Overexpression can lead to cell death, and can contribute to
deformation effects in animal models. However, what happens when Dux4 is expressed at
low level? At what point does the threshold exist? Also, how frequently, and what quantity of
RNA is produced in the event of productive transcription of the Dux4? What are the relative
stabilities of Dux4 mRNA and protein, and to what extent could the Dux4 mRNA itself play a
role in the pathogenicity of the Dux4 mediated disease?

Cell Physiology of FSHD and Correlation to Dux4
There is a decrease in the histone and DNA methylation of the D4Z4 repeats in
FSHD patients, which leads to transcriptional derepression. While the skeletal muscle is the
primary tissue type affected in FSHD, Dux4 can be detected in the non-skeletal muscle cells
in FSHD patients (Snider et al., 2010). The hypomethylation of the D4Z4 repeats in FSHD is
attributed to the action of several different factors which will be discussed here.
One longstanding theory underlying the association of hypomethylation of the D4Z4
repeats with FSHD, as well as the subtelomeric localization of the repeats is that disease
presents due to dysregulated heterochromatin (van der Maarel et al., 2012). Several lines
of evidence support a model in which silenced genomic DNA is being reactivated in somatic
cells in FSHD patients.
In a subset of individuals, mutations in SMCHD1 occurring with 4qA permissive
haplotype result in FSHD2, even in the absence of contractions/reduction of the D4Z4
repeats (Lemmers et al., 2012). The monosomy or mutations identified resulted in
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haploinsuffiency of SMCHD1 due to the presence of less than 50% of the protein.
Consequently, FSHD2 patients with SMCHD1 mutations, showed reduced occupancy of the
protein on the D4Z4 repeats (Lemmers et al., 2012, 2015). SMCHD1 is an essential gene,
and in mice it is embryonic lethal, although in certain genetic backgrounds reduce male
lethality (Mould et al., 2013). This apparent gender disparity in embryonic lethality is a
consequence of the essential role of SMCHD1 in X-chromosome inactivation. SMCHD1 is
recruited at sites with H3K9me3 or H3K9me2 (Brideau et al., 2015), and is potentially a DNA
methylase or essential cofactor for acquired and sustained DNA methylation (Blewitt et al.,
2008; Gendrel et al., 2012). However, not all FSHD2 patients have haploinsuffiency
mutations in SMCHD1, and it has only been recently demonstrated that mutations in
DNMT3B also modify the disease in another set of FSHD2 patients, thus there are likely
other modifiers. It was previously shown that depletion SUV39H1 specifically reduces
H3Kme3 on the D4Z4 repeats (Zeng et al., 2009). Given that SMCHD1 recruitment at the
D4Z4 repeats is H3Kme3 dependent (Zeng et al., 2014), mutations in histone methylase or
demethylase may also modify disease.
Other work has provided some indication that a feed forward mechanism may be at
play to allow for increased derepression of the locus, and thus only a subtle change is
necessary to start a destabilizing cascade. An example that supports this model is DBE-T,
which is a long non-coding RNA detected in FHSD patients that originates from the D4Z4
repeat (Cabianca et al., 2012). DBE-T is likely polyadenylated because of detection in
polyA+ fraction, and thus, is likely an RNA Polymerase II transcript. Fluorescence in situ
hybridization (FISH), shows a faintly nuclear localized, chromatin associated DBE-T and it is
posited to bind the D4Z4 repeats causing derepression. Evidence that supports this model is
that depletion of DBE-T reduces transcription of D4Z4 proximal genes like Ant1 and Frg1, as
well as Dux4. Notably, the function of the RNA in de-repressing the locus cannot be
accomplished in trans. The action of DBE-T is likely mediated through its recruitment of
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histone-lysine N-methyltransferase, ASHL1. ASHL1, a member of the Trithorax complex
was found enriched on non-deleted element (NDE) which lies upstream of the first D4Z4
repeat. In a heterologous host, treated with inhibitors of DNA methylation and histone
acetylation (here referred to as enforced transcriptionally permissive conditions), DBE-T
associates with ASH-L determined by RNA-IP, moreover knockdown of DBE-T reduces
ASHL1 presence at the NDE.
There is potentially a positive feedback effect, wherein, DBE-T production enhances
ASHL-1 recruitment at the NDE, which increases H3K36me2 and thus enhances its own
transcription. In essence creating a trickle effect wherein occasional transcription, which is
enhanced upon deletion of D4Z4 repeats due to more accessibility, allows for more DBE-T
to be produced, which in turn recruits ASHL-1 to further derepress the locus.
However questions remain. First, how is DBE-T processed? Without enforcing
transcriptional permissive conditions, the most abundant transcripts originating for the region
appear discontinuous, therefore is the DBE-T processed to generate smaller RNA species?
Second, what is the timing for the recruitment or the sequence of events that occur to permit
a feedback loop?
At present, a compelling model of FSHD is one in which the D4Z4 repeat locus on
chromosome 4 is a metastable epiallele (Himeda et al., 2014; Jones et al., 2015; Lemmers
et al., 2012), where modified expression of genes at the locus contributes to the etiology of
the disease (Figure 2.3). Key in this model is that, derepression of the somatically repressed
locus in certain chromosomal backgrounds (giving haplotype specificity) allows the
production of a homeodomain transcription factor, Dux4.
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Figure 2.3 Model of Dux4 in FSHD: A Metastable Epiallele. (Top) D4Z4 depicted as
heterochromatin region with negligible transcription due to the histone methylation and DNA
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methylation by DNMT3B, SMCDH1, SUV39H amongst other factors. (Bottom) Dux4 is
derepressed, and the pathogenic splice isoform is enriched due to contractions of the
repeats which alleviate some of the repressive heterochromatin signals or mutations which
impair the function of DNMT3B or SMCDH1. Transcription of lncRNA DBE-T recruits ASHL1
to further derepress the locus. Dux4 is expressed and activates a transcriptional cascade
that includes dysregulated RNA processing – NMD, which stabilizes Dux4-fl mRNA and
potentially increases production of the pathogenic protein product.
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Current State
Genetic variants, epigenetic modifications and RNA splicing contribute to complex
diseases (Li et al., 2016). The transcriptome changes as a consequence of Dux4
expression, the genetic variation modifying disease onset and severity, and the epigenetic
contributions to disease pathology, demonstrate that FSHD may be characterized as a
complex disease.
The current therapies for treatment of FSHD are physiotherapy, dietary
supplementation, corticosteroids and T-cell infiltration (Sacconi et al., 2015; Tawil et al.,
2015) and have resulted in variable success rates. The unclear molecular etiology had long
impaired therapeutic progress. However, the recent advances into the molecular basis of the
disease shows a mosaicism that may not be suitable for a simple panacea and may require
varying strategies for treating and, or preventing the disease. For example, recent reports
have demonstrated in cell culture models, the utility of RNA therapeutics (Lim et al., 2015;
Marsollier et al., 2016), and CRISPR/CAS9 technology (Himeda et al., 2015, 2016) in
suppressing Dux4.
The productive transcription of the Dux4 mRNA in FSHD patients is because of a
SNP which generates a non-consensus PAS. However, beyond the identification of the
PAS, the requirements for efficient 3′ end processing of the Dux4 mRNA have not been
examined. Here, we extend upon these efforts to investigate and characterize the Dux4 3′
end processing signals required for cleavage and polyadenylation. Further, we investigate
the use of utility of RNA therapeutics, in particular cleavage and polyadenylation inhibiting
antisense oligonucleotides to impair processing at the Dux4 polyadenylation signal.
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Chapter 3 : Materials and Methods
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Cloning
Plasmids used in the study are described in Table 3.1. In the majority of constructs
traditional restriction enzyme cloning was used to generate reporters. Primers and
oligonucleotides used for cloning are described in Table 3.2. Inserted DNA was amplified
using Pfu polymerase (purified by the Wagner Laboratory), and gel purified using GeneJet
Gel Purification System (Thermo Fisher Scientific, Massachusetts USA). The SV40 late
polyadenylation signal was amplified using the pGL4.13 (Promega, Wisconsin USA).
Putative Dux4 processing signals were amplified from p2loxDux4 that was kindly provided
by the Kyba Laboratory (Bosnakovski et al., 2008). Dux4 3′ UTRs and cDNA sequences
were obtained from ensembl.org and cross referenced with Ref Seq. The Dux4 UTR
constructs and the Dux4 cDNA were artificially synthesized by GenScript (New Jersey, USA)
and subcloned into the appropriate vector. All clones were sequenced to confirm identity.
In the remaining constructs, annealed oligonucleotide cloning was used and
proceeded as follows: unphosphorylated polyacrylamide gel electrophoresis (PAGE) purified
oligonucleotides were mixed equimolar at 20µM in annealing buffer (100mM Tris pH 7.5, 1M
NaCl, 10mM EDTA). The mixture was heated to 95˚C and then using a thermocycler the
temperature was ramped down 5˚C per cycle for three minutes per cycle, to a final
temperature of 25˚C. 5µL of the annealed oligonucleotides was then incubated at 37˚C for
30 minutes with T4 Polynucleotide Kinase (New England Biolabs, Massachusetts USA) and
10µM ATP (Thermo Fisher Scientific) for phosphorylation. The phosphorylated annealed
oligonucleotide was diluted 1:1000 and ligated to the appropriate alkaline phosphatase
treated vector. Ligation reactions were carried out using T4 Ligase (purified by the Wagner
Laboratory). Ligations were transformed into XL-1 Blue Competent cells (Stratagene,
California USA).
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In some constructs site-directed mutagenesis was performed to remove cryptic start
codons, or introduce defects in the polyadenylation cis elements. In brief, to perform sitedirected mutagenesis 10-25 ng of template plasmids were used for PCR using
oligonucleotides for site directed mutagenesis listed in Table 3.2 in a total volume of 25µL
using Pfu polymerase. Methylated template DNA was digested with 1µL DpnI (Thermo
Fisher Scientific) for thirty minutes. Following Dpn I digestion, 1µL of the PCR product was
transformed in XL1-Blue Competent Cells.
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Table 3.1. Table of Plasmids
Name

Source/Reference

pcDNA3.1(+)

Courtesy of the Jayaraman Lab, University of Texas
McGovern Medical School

p2loxDux4

Courtesy of the Kyba Lab, Lillehei Heart Institute,
University of Minnesota

pLentiDuxBSntGFP

Acquired from the Miller Lab, University of Washington

pcDNA6tr

Invitrogen

pcDNA3

Invitrogen

pdp20

Derived by Dr. Eric J. Wagner from pdp19 vector
initially purchased from Ambion

pTZHIVdGless

Suñe Lab, Instituto de Parasitología y Biomedicina
“López Neyra”, Consejo Superior de Investigaciones
Científicas (IPBLN-CSIC), PTS, Granada, Spain

psiCheck2

Promega

pgl4.13

Promega

pUC19

NEB

pGINT

Addgene

pUC57-Kan-Dux4ORF

Genscript

pUC57-Kan-Dux4UTR1

Genscript

pUC57-Kan-Dux4UTR2

Genscript

pUC57-Kan-Dux4UTR-Int2minus Genscript
pUC57-Kan-Dux4UTRunspliced

Genscript
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Table 3.2. Table of DNA Oligonucleotides for Cloning
Name

Purpose

Sequence

N060

Annealled Oligo Cloning of

GCCGGCGTCCTGGTATCCAATCCT

Hammerhead ribozyme

TCGGGATGTACTACCAGCTGATGA
GTCCCAAATAGGACGAAACGCCGG
A

N061A

Annealled Oligo Cloning of

AGCTTCCGGCGTTTCGTCCTATTTG

Hammerhead ribozyme

GGACTCATCAGCTGGTAGTACATC
CCGAAGGATTGGATACCAGGACGC
CGGCTGCA

N078

Cloning CMV Promoter

GCCGAATTCGCGTTGACATTGATTA
TTGAC

N079

Cloning CMV Promoter

GGCCGAATTCGAGCTCTGCTTATAT
AGACCT

N0D19

Cloning Dux4PAS

GGCCGCGGCCGCTACATATCTCTA
CACTGATCACGTAAGTGATGTA

N0D20

Cloning Dux4PAS

GGCCAAGCTTCTTCCGTGAAATTCT
GGCTGAATGTCTCC

N0D21

Cloning Dux4PAS

GGCCGCGGCCGCTACCAATTTCAG
GCTTTTTGTACAGGGGATA

N0D22

Cloning Dux4PAS

GGCCAGATCTCTTCCTGGCTAGAC
CTGCGC

N0D23

Cloning Dux4PAS

GGCCAGATCTTTCTATAGGATCCAC
AGGGAGGG
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N0D18B

Cloning Dux4PAS

GGCCAAGCTTTAGACCTGCGCGCA
GTGCGCACCCC

N0D24

Cloning Dux4PAS

GGCCAGATCTCGAGTAGACCTGCG
CGCAGTGCGCACCCC

N0D25

Cloning Dux4PAS

GGCCAGATCTACATATCTCTACACT
GATCAC

N0D26

Cloning Dux4PAS

GGCCAGATCTCGAGCTTCCGTGAA
ATTCTGGCTGAATGTCTCC

N0D27

Cloning Dux4PAS

GGCCAGATCTACCAATTTCAGGCTT
TTTCTACAGGGGATA

N0D28

Cloning Dux4PAS

CATCTCCTGGATGATTACTTCAGAG
ATATATTAAAATGCCC

N0D29

Cloning Dux4PAS

GGGCATTTTAATATATCTCTGAAGT
AATCATCCAGGAGATG

N0D30

Cloning Dux4PAS

GTCACAATATCCCCTGTACAAAAAG
CCTGAAATTGG

N0D31

Cloning Dux4PAS

CCAATTTCAGGCTTTTTGTACAGGG
GATATTGTGAC

N0D32

Cloning Dux4PAS

GGCCAGATCTATCGATTGCCTACA
CTCTGCCTACAGGAGGC

N0D33

Cloning Dux4PAS

GGCCAGATCTCGAGATCGATTAGA
CCTGCGCGCAGTGCGCAC

N0D34

Cloning Dux4PAS

GGCCGCGGCCGCTTTAAGTGATGT
AACCATTCTC
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N0D35

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTCAGTC
TACTATGG

N0D36

Cloning Dux4PAS

GGCCGCGGCCGCTGAGTTCTGAAA
CACATCTGC

N0D37

Cloning Dux4PAS

GGCCGCGGCCGCTGCACTGATCAC
CGAAGTTATG

N0D34B

Cloning Dux4PAS

GGCCGCGGCCGCTGTAAGTGATGT
AACCATTCTC

N0D92

Cloning Dux4PAS

GGCCTCTAGATTAAGTGATGTAACC
ATTCTC

N0D93

Cloning Dux4PAS

GGCCTATAGATAGGTTCAGTCTACT
ATGG

N0D94

Cloning Dux4PAS

GGCCTCTAGAGAGTTCTGAAACAC
ATCTGC

N0D95

Cloning Dux4PAS

GGCCTCTAGAGCACTGATCACCGA
AGTTATG

N0D96

Cloning Dux4PAS

GGCCTCTAGAACCAATTTCAGGCTT
TTTGTACAGGGGATA

N0D97

Cloning Dux4PAS

GGCCCTCGAGTAGACCTGCGCGCA
GTGCGCACCCC

N0D98

Cloning Dux4PAS

GGCC GGATCC
TAGACCTGCGCGCAGTGC

N0D106

Cloning Dux4PAS

GGCCGAATTCTAGACCTGCGCGCA
GTGCGCAC
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N0D107

Cloning Dux4PAS

GGCCCTCGAGACATATCTCTACACT
GATCAC

N0D108

Cloning Dux4PAS

GGCCCTCGAG
CTATAGGATCCACAGGGAG

N0D109

Cloning Dux4PAS

GGCCCTCGAGGCACTGATCACCGA
AGTTATG

N0D111

Cloning Dux4PAS

GGCCGAATTCCTTCCGTGAAATTCT
GGCTGAATGTCTCC

N0D120

Cloning Dux4PAS

CATGCGGCCGCTCACGCGCTCTAC
ACTGATCACGTAAGTGATG

N0D121

Cloning Dux4PAS

CATGCGGCCGCTACATATAGAGCA
ACTGATCACGTAAGTGATG

N0D122

Cloning Dux4PAS

GGCCGCGGCCGCTACTGATCACGT
AAGTGATGTAAC

N0D145

Cloning Dux4PAS

CATGCGGCCGCTAAATATCTCTACA
CTGAT

N0D125

Cloning Dux4PAS

GGCCGCGGCCGCTCTCTACACTGA
TCACGTAAGTG

N0D144

Cloning Dux4PAS

CATGCGGCCGCTCCATATCTCTAC
ACTGAT

N0D146

Cloning Dux4PAS

CATGCGGCCGCTACCTATCTCTAC
ACTGAT

N0D147

Cloning Dux4PAS

CATGCGGCCGCTACAGATCTCTAC
ACTGATCAC
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N0D148

Cloning Dux4PAS

CATGCGGCCGCTACATCTCTCTAC
ACTGATCAC

N0D149

Cloning Dux4PAS

CATGCGGCCGCTACATAGCTCTAC
ACTGATCAC

N0D150

Cloning Dux4PAS

GGCCGCGGCCGCTACATATATCTA
CACTGATCACGTAAGT

N0D151

Cloning Dux4PAS

GGCCGCGGCCGCTACATATCGCTA
CACTGATCACGTAAGT

N0D152

Cloning Dux4PAS

GGCCGCGGCCGCTACATATCTGTA
CACTGATCACGTAAGT

N0D153

Cloning Dux4PAS

GGCCGCGGCCGCTACATATCTCTA
CCCTGATCACGTAAGTGAT

N0D154

Cloning Dux4PAS

GGCCGCGGCCGCTACATATCTCTA
CAATGATCACGTAAGTGAT

N0D155

Cloning Dux4PAS

GGCCGCGGCCGCTACATATCTCTA
CACGGATCACGTAAGTGAT

N0D156

Cloning Dux4PAS

GGCCATCGATTAGACCTGCGCGCA
GTGCGCACCCC

N0D157

Cloning Dux4PAS

GGCCATCGATCTTCCGTGAAATTCT
GGCTGAATGTCTCC

NOD163

Cloning Dux4PAS

GGCCAAGCTTACATATCTCTACACT
GATCACGTAAGTGATGTA

NOD164

Cloning Dux4PAS

GGCCAAGCTTACCAATTTCAGGCTT
TTTGTACAGGGGATA
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NOD165

Cloning Dux4PAS

GGCCAAGCTTTGCCTACACTCTGC
CTACAGGAGGC

NOD36B

Cloning Dux4PAS

GGCCGCGGCCGCTGAGTTCTGAAA
CAGATCTGC

NOD167

Cloning Dux4PAS

GGCCAAGCTTAGGGGCTTTGTGAG
ATATCTCTG

NOD168

Cloning Dux4PAS

GGCCAAGCTTATTTCCACTGCTCAA
ACAGGTGATG

NOD169

Cloning Dux4PAS

GGCCAAGCTTGAGATGTAAAAATTG
TCTGGGCTTTGTC

NOD170

Cloning Dux4PAS

GGCCAAGCTTAAGCTCTGCCTACA
GGGGCATTG

NOD173

Cloning Dux4PAS

GGCCGCGGCCGCTTCGGTTCAGTC
TACTATGGAGTTC

NOD174

Cloning Dux4PAS

GGCCGCGGCCGCTTAGTGGCAGT
CTACTATGGAGTTC

NOD175

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTACTTC
TACTATGGAGTTC

NOD176

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTCAGGA
GACTATGGAGTTC

NOD177

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTCAGTC
TCAGATGGAGTTC

NOD178

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTCAGTC
TACTCGTGAGTTC
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NOD179

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTCAGTC
TACTATGTCTTTC

NOD181

Cloning Dux4PAS

GGCCGCGGCCGCTGCTTGGCAGT
CTACTATGGAGTTCTGAAAC

NOD182

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTACTGA
GACTATGGAGTTCTGAAAC

NOD183

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTCAGTC
TCAACGTGAGTTCTGAAAC

NOD178B

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTCAGTC
TACTCGTGAGTTC TGAAAC

NOD179B

Cloning Dux4PAS

GGCCGCGGCCGCTTAGGTTCAGTC
TACTATGTCTTTCTGAAAC

NOD189

Cloning Dux4PAS

GGCCAGATCTAGGGGCTTTGTGAG
ATATCTCTG

NOD195

Cloning Dux4PAS

GGCCGCGGCCGCTAAATATCTCTA
CCAGACGCACGTA

NOD196

Cloning Dux4PAS

GGCCGCGGCCGCTAAATATAGAGC
AACTGATCACGTA

NOD197

Cloning Dux4PAS

GGCCGCGGCCGCTCGCGCGCTCT
ACACTGATCACGTA

NOD225

Cloning Dux4PAS

GGCCGCGGCCGCTCACGCTCTCTA
CACTGATCACGTA

NOD223a

Cloning Dux4PAS

GGCCGCGGCCGCTAAATATCTCTC
ACAGGATCACGTA
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NOD224a

Cloning Dux4PAS

GGCCGCGGCCGCTAAATAGAGAGA
CACTGATCACGTA

NOD226

Cloning Dux4PAS

GGCCGCGGCCGCTGAACTAATCAT
CCAGGAGATG

NOD227

Cloning Dux4PAS

GGCCCTCGAGACCTGCGCGCAGT
GCGCACC

NOD228

Cloning Dux4PAS

GGCCCTCGAGCTTCCGTGAAATTC
TGGC

N0D08

Cloning Dux4PAS Exon3

GGCCAGATCTTTCTATAGGATCCAC
AGGGAGGG

N0D17

Cloning Dux4PAS Exon3

GGCCGCGGCCGCTTGCGTACACTC
TGCCTACAGGAGGC

N0D01B

Cloning Dux4PAS pLAM

GGCCAAGCTTCGGTCAAAAGCATA
CCTCTGTCTGTCT

N054

Cloning HAmCherry

GGCCGGTACCATGTACCCATACGA
TGTTCCTGACTATGCGGGCGTGAG
CAAGGGCGAG

N055

Cloning HAmCherry

GGCCGGATCCTTACTTGTACAGCT
CGTCCATG

N081

N082

N083

Cloning Random Sequences from

GGCCAAGCTTGTGATGACGGTGAA

pUC19

AACCTC

Cloning Random Sequences from

GGCCGGATCCGTACAATCTGCTCT

pUC19

GATGCC

Cloning Random Sequences from

GGCCAAGCTTGAGAGTGCACCATA

pUC19

TGCGGT
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N084

N085

N086

N087

N088

N089

N090

N091

N092

N081p

N083p

N085p

Cloning Random Sequences from

GGCCGGATCCCAACGTCGTGACTG

pUC19

GGAAAACCCTGGCGTT

Cloning Random Sequences from

GGCCAAGCTTATGTTGTGCAAAAAA

pUC19

GCGGTTAGCTCCTTC

Cloning Random Sequences from

GGCCGGATCCGAATGACTTGGTTG

pUC19

AGTACT

Cloning Random Sequences from

GGCCAAGCTTATGATACCGCGAGA

pUC19

CCCACG

Cloning Random Sequences from

GGCCGGATCCGGCAACAACGTTGC

pUC19

GCAAACTATTAACTGG

Cloning Random Sequences from

GGCCGGATCCTTTAAAAGTGCTCAT

pUC19

CATTG

Cloning Random Sequences from

GGCCAAGCTTATGAGTATTCAACAT

pUC19

TTCCGTG

Cloning Random Sequences from

GGCCAAGCTTGGGTGCCTAATGAG

pUC19

TGAGCT

Cloning Random Sequences from

GGCCGGATCCGAGGAAGCGGAAG

pUC19

AGCGCCCAATACGCAAA

Cloning Random Sequences from

GGCCAGATCTGTGATGACGGTGAA

pUC19

AACCTC

Cloning Random Sequences from

GGCCAGATCTGAGAGTGCACCATA

pUC19

TGCGGT

Cloning Random Sequences from

GGCCAGATCTATGTTGTGCAAAAAA

pUC19

GCGGTTAGCTCCTTC
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N087p

N089p

N091p

N050

Cloning Random Sequences from

GGCCAGATCTATGATACCGCGAGA

pUC19

CCCACG

Cloning Random Sequences from

GGCCAGATCTTTTAAAAGTGCTCAT

pUC19

CATTG

Cloning Random Sequences from

GGCCAGATCTGGGTGCCTAATGAG

pUC19

TGAGCT

Cloning SV40LPAS

GGCCAAGCTTGCCGTGTAATAATTC
TAGAGTC

N051

Cloning SV40LPAS

GGCCGGATCCGAAAACCTCCCACA
CCTCCCC

N0120

Cloning SV40LPAS

GGCCATCGATGCCGTGTAATAATTC
TAGAGT C

N0121

Cloning SV40LPAS

GGCCGGATCCGAAAACCTCCCACA
CCTCCCC

N0122

Cloning SV40LPAS

GGCCGGATCCCGATTTTACCACATT
TGTAGAGG

N0145

Cloning SV40LPAS

GGCCATCGATGAGTTTGGACAAAC
CACAAC

N0146

Cloning SV40LPAS

GGCCATCGATGCAGCTTATAATGG
TTACAAAT

N0147

Cloning SV40LPAS

GGCCAAGCTTCAACAATTGCATTCA
TTTTATGTTTC

N099

Cloning SV40LPAS

GGCCAGATCTGAAAACCTCCCACA
CCTCCCC
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N0121B

Cloning SV40LPAS

GGCCAAGCTTGAAAACCTCCCACA
CCTCCCC

N0122B

Cloning SV40LPAS

GGCCAAGCTTCGATTTTACCACATT
TGTAGAGG

N080

Cloning SV40LPAS DSE null

GGCCGTCGACATTGTTGTTGTTAAC
TTGTTTATTGC

N069

Cloning SV40LPAS DSE null

GGCCGGATCCATTGTTGTTGTTAAC
TTGTTTATTGC

N0150A

N0150B

N0149A

N0149B

N076

N077

N074

N075

Site directed mutagenesis create ClaI

CTCCTGGATGATTAGTTCATCGATA

restriction site in Dux4PAS

TATTAAAATGCCCCCTCCCT

Site directed mutagenesis create ClaI

AGGGAGGGGGCATTTTAATATATC

restriction site in Dux4PAS

GATGAACTAATCATCCAGGAG

Site directed mutagenesis create

GTGGATCCTATAGAAGATTTGAAGC

HindIII restriction site in Dux4PAS

TTTTGTGTGATGAGTGCAG

Site directed mutagenesis create

CTGCACTCATCACACAAAAGCTTCA

HindIII restriction site in Dux4PAS

AATCTTCTATAGGATCCAC

Site directed mutagenesis create

GCAATAAACAAGTTAACGGCGGCG

SV40L clvnull short oligo

GTTGCATTCATTTTATG

Site directed mutagenesis create

CATAAAATGAATGCAACCGCCGCC

SV40L clvnull short oligo

GTTAACTTGTTTATTGC

Site directed mutagenesis create

GTAACCATTATAAGCTGCGGGAAA

SV40L PASNull short oligo

CAAGTTAACAAC

Site directed mutagenesis create

GTTGTTAACTTGTTTCCCGCAGCTT

SV40L PASNull short oligo

ATAATGGTTAC
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N0D113A

Site directed mutagenesis Dux4PAS

CTCCATAGTAGACTGAACCTATCTC
CTGGTTACATCACTTAC

N0D113B

Site directed mutagenesis Dux4PAS

GTAAGTGATGTAACCAGGAGATAG
GTTCAGTCTACTATGGAG

N0D114A

Site directed mutagenesis Dux4PAS

GTAGACTGAACCTAGAGAAGTTGG
ACATCACTTACGTGATCAG

N0D114B

Site directed mutagenesis Dux4PAS

CTGATCACGTAAGTGATGTCCAACT
TCTCTAGGTTCAGTCTAC

N0D115A

Site directed mutagenesis Dux4PAS

CTGAACCTAGAGAATGGTTCACGA
ACTTACGTGATCAGTGTAGAG

N0D115B

Site directed mutagenesis Dux4PAS

CTCTACACTGATCACGTAAGTTCGT
GAACCATTCTCTAGGTTCAG

N0D116A

Site directed mutagenesis Dux4PAS

CTAGAGAATGGTTACATCCAGGCC
GTGATCAGTGTAGAGATATG

N0D116B

Site directed mutagenesis Dux4PAS

CATATCTCTACACTGATCACGGCCT
GGATGTAACCATTCTCTAG

N0D117A

Site directed mutagenesis Dux4PAS

GAGAATGGTTACATCACTTAATGTC
TCAGTGTAGAGATATGTAGC

N0D117B

Site directed mutagenesis Dux4PAS

GCTACATATCTCTACACTGAGACAT
TAAGTGATGTAACCATTCTC

N0D117C

Site directed mutagenesis Dux4PAS

GAGAATGGTTACATCACTTATTGTC
TCAGTGTAGAGATATGTAGC

N0D117D

Site directed mutagenesis Dux4PAS

GCTACATATCTCTACACTGAGACAA
TAAGTGATGTAACCATTCTC
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N0D118A

Site directed mutagenesis Dux4PAS

GGTTACATCACTTACGTGAGACTG
GTAGAGATATGTAGC

N0D118B

Site directed mutagenesis Dux4PAS

GCTACATATCTCTACCAGTCTCACG
TAAGTGATGTAACC

NOD166A

Site directed mutagenesis Dux4PAS

GTTACATCTCCTGGAGGATTACTTC
AGAGATATATTAAAATCCCC

NOD166B

Site directed mutagenesis Dux4PAS

GGGGATTTTAATATATCTCTGAAGT
AATCCTCCAGGAGATGTAAC

NOD112C

Site directed mutagenesis Dux4PAS

CATTACTTCAGAGATATATTTAAATC
CCCCCTCCCTGTG

NOD112D

Site directed mutagenesis Dux4PAS

CACAGGGAGGGGGGATTTAAATAT
ATCTCTGAAGTAATG

NOD180A

Site directed mutagenesis Dux4PAS

GATCATTACTTCAGAGATATAGGGA
AATCCCCCCTCCCTGTG

NOD180B

Site directed mutagenesis Dux4PAS

CACAGGGAGGGGGGATTTCCCTAT
ATCTCTGAAGTAATGATC

NOD190A

Site directed mutagenesis Dux4PAS

CAGAACTCCATAGTAGACTGCCAA
GCGAGAATCGTTACATCTACGTGAT
C

NOD190B

Site directed mutagenesis Dux4PAS

GATCACGTAGATGTAACGATTCTCG
CTTGGCAGTCTACTATGGAGTTCTG

NOD191A

Site directed mutagenesis Dux4PAS

CTCCATAGTAGACTGAACCTATCTC
CGCGTTACATCACTTACGTGATCAG
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NOD191B

Site directed mutagenesis Dux4PAS

CTGATCACGTAAGTGATGTAACGC
GGAGATAGGTTCAGTCTACTATGG
AG

NOD192A

Site directed mutagenesis Dux4PAS

CCATAGTAGACTGAACCTAGAGAAT
ATCTACATCACTTACGTGATCAGTG

NOD192B

Site directed mutagenesis Dux4PAS

CACTGATCACGTAAGTGATGTAGAT
ATTCTCTAGGTTCAGTCTACTATGG

NOD192C

Site directed mutagenesis Dux4PAS

CCATAGTAGACTGAACCTAGAGAAT
ATCGCAATCACTTACGTGATCAGTG

NOD192D

Site directed mutagenesis Dux4PAS

CACTGATCACGTAAGTGATTGCGAT
ATTCTCTAGGTTCAGTCTACTATGG

NOD193A

Site directed mutagenesis Dux4PAS

GTAGACTGAACCTAGAGAATCGTTA
CCGACAGTACGTGATCAGTGTAGA
G

NOD193B

Site directed mutagenesis Dux4PAS

CTCTACACTGATCACGTACTGTCGG
TAACGATTCTCTAGGTTCAGTCTAC

NOD194A

Site directed mutagenesis Dux4PAS

CCTAGAGAATCGTTACATCACTGCA
GTGATCAGTGTAGAGATATTTTG

NOD194B

Site directed mutagenesis Dux4PAS

CAAAATATCTCTACACTGATCACTG
CAGTGATGTAACGATTCTCTAGG

NOD194C

Site directed mutagenesis Dux4PAS

CCTAGAGAATCGTTACATCACTGCA
TATATCAGTGTAGAGATATTTTG

NOD194D

Site directed mutagenesis Dux4PAS

CAAAATATCTCTACACTGATATATG
CAGTGATGTAACGATTCTCTAGG
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NOD214A

Site directed mutagenesis Dux4PAS

CAGATCTGTTTCAGAACTCACGCTT
AGACTGAACCTAGAGAATC

NOD214B

Site directed mutagenesis Dux4PAS

GATTCTCTAGGTTCAGTCTAAGCGT
GAGTTCTGAAACAGATCTG

NOD215A

Site directed mutagenesis Dux4PAS

CTGTTTCAGAACTCCATAGGCTCGT
GAACCTAGAGAATCGTTAC

NOD215B

Site directed mutagenesis Dux4PAS

GTAACGATTCTCTAGGTTCACGAGC
CTATGGAGTTCTGAAACAG

NOD216A

Site directed mutagenesis Dux4PAS

CAGAACTCCATAGTAGACGTCCACT
AGAGAATCGTTACATCAC

NOD216B

Site directed mutagenesis Dux4PAS

GTGATGTAACGATTCTCTAGTGGAC
GTCTACTATGGAGTTCTG

NOD217A

Site directed mutagenesis Dux4PAS

CTCCATAGTAGACTGAACAGCTCG
AATCGTTACATCACTTACGTG

NOD217B

Site directed mutagenesis Dux4PAS

CACGTAAGTGATGTAACGATTCGA
GCTGTTCAGTCTACTATGGAG

NOD218A

Site directed mutagenesis Dux4PAS

CTCCATAGTAGACTGAACCTAGATC
CTAGTTACATCACTTACGTG

NOD218B

Site directed mutagenesis Dux4PAS

CACGTAAGTGATGTAACTAGGATCT
AGGTTCAGTCTACTATGGAG

NOD219A

Site directed mutagenesis Dux4PAS

GTAGACTGAACCTAGAGAATCTGG
CAATCACTTACGTGATCAGTG

NOD219B

Site directed mutagenesis Dux4PAS

CACTGATCACGTAAGTGATTGCCA
GATTCTCTAGGTTCAGTCTAC
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NOD220A

Site directed mutagenesis Dux4PAS

GAACCTAGAGAATCGTTACCGACAT
TACGTGATCAGTGTAGAG

NOD220B

Site directed mutagenesis Dux4PAS

CTCTACACTGATCACGTAATGTCGG
TAACGATTCTCTAGGTTC

NOD221A

Site directed mutagenesis Dux4PAS

CTAGAGAATCGTTACATCACGGCAT
TGATCAGTGTAGAGATATC

NOD221B

Site directed mutagenesis Dux4PAS

GATATCTCTACACTGATCAATGCCG
TGATGTAACGATTCTCTAG

NOD222A

Site directed mutagenesis Dux4PAS

GAATCGTTACATCACTTACGGTCGA
AGTGTAGAGATATCTAGCG

NOD222B

Site directed mutagenesis Dux4PAS

CGCTAGATATCTCTACACTTCGACC
GTAAGTGATGTAACGATTC

N066

N067A

N064

N065A

N093

N094

Site-directed mutagenesis remove

CCGCTTCGAGCAGACGTGATAAGA

start codon in SV40LPAS

TACATTGATGAGTTTGG

Site-directed mutagenesis remove

CCAAACTCATCAATGTATCTTATCA

start codon in SV40LPAS

CGTCTGCTCGAAGCGG

Site-directed mutagenesis remove

CCACAACTAGAATGCAGGGAAAAA

stop codon in SV40LPAS

AATGCTTTATTTGTG

Site-directed mutagenesis remove

CACAAATAAAGCATTTTTTTCCCTG

stop codon in SV40LPAS

CATTCTAGTTGTGG

Site-directed mutagenesis remove

GGACAAACCACAACTAGAGTGCAG

stop codon in SV40LPAS

GGA AAAAAATGC

Site-directed mutagenesis remove

GCATTTTTTTCCCTGCACTCTAGTT

stop codon in SV40LPAS

GTGGTTTGTCC
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N095

N096

Site-directed mutagenesis remove

TGCATTCATTTTGTGTTTCAGGTTC

stop codon in SV40LPAS

AGGGGGAGGTG

Site-directed mutagenesis remove

CACCTCCCCCTGAACCTGAAACAC

stop codon in SV40LPAS

AAAATGAATGCA
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Cell Culture
All cell lines used in this study are described in Table 3.3. Patient cell lines were
obtained from University of Rochester and University of Massachusetts Wellstone Center for
FSHD. Patient cells were supplied as de-identified lines by the aforementioned institutes.
HeLa, HEK293T and RD cells were cultured in Dulbecco’s modified Eagle medium (DMEM)
(Lonza, Maryland USA) containing L-Glutamine and Sodium pyruvate and supplemented
with 1% penicillin-streptomycin (Thermo Fisher Scientific) and 10% fetal bovine serum
(Hyclone, Utah USA). Hereafter, referred to as DMEM Complete. Cells were passaged 1:10
and grown in 5% CO2.
Immortalized myoblast cells obtained from the Wellstone Center for FSHD were
culture in LHCN , Medium (4:1 DMEM: Medium 199, supplemented with 20% fetal bovine
serum, 30 mg/L ZnSO4 (Sigma, Missouri USA), 1.4 mg/mL Vitamin B12 (Sigma, Missouri
USA), 55µg/mL dexamethasone (Sigma, Missouri USA), 2.5 µg/mL hepatocyte growth factor
(Sigma), 25 µg/mL basic fibroblast growth factor (Promega, Wisconsin, USA) and 1%
antibiotic/antimycotic (Thermo Fisher Scientific, Massachusetts USA). For differentiation,
cells at ≥90% confluence were fed 4:1 DMEM:Medium 199 supplemented with 2% horse
serum (Hyclone, Utah USA) or 15% Knock-Out Serum Replacer (Thermo Fisher Scientific,
Massachusetts USA), 2 mM L-glutamine (Thermo Fisher Scientific, Massachusetts USA),
1% antibiotics/antimycotics, 20 mM HEPES (Sigma, Missouri USA) and 1 mM sodium
pyruvate (Thermo Fisher Scientific, Massachusetts USA). Immortalized human myoblast
cells were grown on plates treated with 0.1% gelatin.
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Table 3.3. Table of Cell Lines
Cell Line

Supplier

Descriptor

Reference

HeLa

ATCC

Immortalized human

HeLa (ATCC® CCL2™)

cervical cancer cell line
HEK293T

ATCC

Immortalized human

293T (ATCC® CRL3216™)

embryonic kidney cells
containing the SV40 large T
antigen
RD

ATCC

Immortalized human

RD (ATCC® CCL136™)

rhabdomyosarcoma striated
muscle cell line
15Abic

University of

Immortalized human

(Homma et al., 2012;

Ct#24

Massachusett

skeletal muscle cell line:

Rahimov et al., 2012; Stadler

s Wellstone

myoblasts. FSHD line

et al., 2011)

Program

derived from proband with
~8 D4Z4 repeats.

15Vbic

University of

Immortalized human

(Homma et al., 2012;

CT#9

Massachusett

skeletal muscle cell line:

Rahimov et al., 2012; Stadler

s Wellstone

myoblasts. Control line

et al., 2011)

Program

derived from unaffected
sibling of 15Abic line.
Normal D4Z4 repeat length
>11.
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Stable Line Development
A kill curve was performed on HEK293T cells and the optimal dose for selecting
resistance within 6 days using blasticidin (Thermo Fisher Scientific, Massachusetts USA)
was 10 mg/mL. HEK239T cells were plated at 6x105 cells per well in 6 well dish, and
transfected the following day with the reporter plasmid and selection plasmid (10:1 ratio)
using Polyethylenimine (PEI). After a period of 24 hrs after transfection, visual confirmation
of the expression of the selection plasmid (mCherry) and the reporter plasmid (GFP) was
done. The medium was then removed from the cells and replaced with DMEM complete
containing blasticidin at 10 µg/mL. Cells were allowed to grow in selection in six-well dish for
a week with medium replenished every other day. After day six, cells were moved to 10 cm2
dish, while still maintaining selection. Cells were allowed to grow to generate sufficient
plates for freezing down and cell sorting. Within two days of moving to 10 cm2 dish, cell
selection was maintained using a lower dose of Blasticidin (5 µg/ml) with each passage in
DMEM complete. Cells plated for transfection with ASOs or siRNAs were seeded in DMEM
complete without blasticidin. Polyclonal cells were sorted at the University of Texas Medical
Branch Flow Cytometry and Cell Sorting Core Facility for GFP positive cells. To select clonal
cells, cells were seeded at a density of 0.5 cell/ well in 96 well dish in the absence of
blasticidin. After sufficient growth, indicated by a change in the color of the medium clones
were moved to a 24-well dish and supplemented with 5 µg/mL blasticidin. The clonal identity
was determined by sequencing of nested PCR products amplified from the genomic DNA of
the clones.
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Transfections
All cells were transiently transfected with Lipofectamine 2000 (Thermo Fisher
Scientific, Massachusetts USA) or with Polyethylenimine (PEI) (Sigma, Missouri USA). Cells
were transfected at 70-80% confluence.

Small Interfering RNA (siRNA) transfections
All siRNAs used in this study are listed in Table 3.4, and were purchased from
Sigma-Aldrich. A two hit protocol (Albrecht and Wagner, 2012; Wagner and Garcia-Blanco,
2002) was used for transfection of siRNAs (Figure 3.1A). Briefly, cells were seeded the day
before transfection to ensure 80% confluence on day of transfection in a 24-well plate. A
total of 3 µL of Lipofectamine 2000 was incubated with 50µL of OptiMEM (Thermo Fisher
Scientific) for seven minutes at room temperature. After seven minutes elapsed, the
Lipofectamine/OptiMEM mixture was mixed with an equal volume of OptiMEM containing 3
µL of 20 µM siRNA. The siRNA:lipid complexes were allowed to form during a 25 minute
incubation at room temperature. After which, the complexes were added to cells. Final
concentration of siRNA on cells 100 nM. The medium was changed four hours after
transfection. Twenty-four hours after transfection, the cells were trypsinized and moved to a
six-well plate. Following an additional twenty-four hours of growth, cells were once more
transfected with siRNA as described earlier for final concentration of 100 nM siRNA. In some
instances at the second transfection, siRNA was co-transfected with DNA plasmids that
were typically 100 ng of reporter plasmid with 50ng transfection control plasmid. Cells were
lysed for protein or RNA 24-48 hrs after second transfection.
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Table 3.4. Table of siRNAs
Name

Sequence

Reference

C2

GGUCCGGCUCCCCCAAAUG[dT][dT]

(Wagner et al., 2005)

XRN1

GUAACUGAACUUUCUCGAA[dT][dT]

Sigma-Aldrich #1

Exosc4

GACCGUAAGUCCUGAGA[dT][dT]

Sigma-Aldrich #1

siGFP

CAAGCUGACCCUGAAGUUC[dT][dT]

(Tschuch et al., 2008)

Dicer1

CAUUGAUCCUGUCAUGGAU[dT][dT]

Sigma-Aldrich #1

CPSF160

GCUUUAAGAAGGUCCCUCA[dT][dT]

Sigma-Aldrich #1

UPF1

GAGAUAUGCCUGCGGUACA[dT][dT]

Sigma-Aldrich #1

CstF64

GGCUUUAGUCCCGGGCAGA[dT][dT]

Sigma-Aldrich #1
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Figure 3.1. Schematic of transfection protocol with co-transfection of siRNA or ASO with
Reporter. A and B are two hit protocols, C is a single hit protocol for transfections
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Antisense Oligonucleotide (ASO) transfections
All ASO are listed in Table 3.5, and were purchased from Sigma-Aldrich with either a
phosphorothioate or phosphodiester backbone. ASOs were transfected with a two-hit
protocol as described above for siRNA transfection. Lipofectamine 2000 volume was
typically kept constant at 3 µL and ASO volume maintained below 5 µL, and if necessary
diluted in ultrapure water for the required concentration. Modifications to the ASO
transfections include only a single transfection of ASO in 24 well plated cells, with cells lysed
for RNA or protein or visualized for fluorescence 24-120 hrs (120 hrs post transfection used
for myoblast transfected ASOs which were induced to differentiate). Another modification of
the ASO transfection protocol (Figure 3.1B/C) occurs when reporter and transfection control
plasmid are first transfected into cells plated in a 24-well dish, described below. Plasmid
transfected cells are moved to a 6-well dish and transfected with ASO at the appropriate
concentration.

74

Table 3.5. Table of Antisense Oligonucleotides
Name

Sequence

Bac
kbone

Targ

Refe

et

rence

SV40PAS

This study

[mG][mU][mU][mA][mA][mC][mU][mU][mG][mU][mU][mU][mA][mU]
PS, PO
NPASO -1

[mU][mG][mC][mA]

ASO
[mG][mC][mA][mA][mU][mU][mA][mG][mU][mA][mA][mA][mU][mU][
PS, PO

Control

mC]
Short

NPASO -2

This study

ASO
Control
[Flc][mG][mC][mA][mA][mU][mU][mA][mG][mU][mA][mA][mA][mU][
NPASO-2F

PS

Short

mU][mC]
'5Fluorecein
Tag

This study

ASO
[mU][mU][mG][mC][mA][mA][mU][mU][mA][mG][mU][mA][mA][mA][
PS, PO

Control

mU][mU][mC][mA]
NPASO -3

Long

This study
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[mG][mC][mA][mU][mU][mU][mU][mA][mA][mU][mA][mU][mA][mU][

Dux4PAS at
PS

NPASO -4

mC]

PAS

This study

Dux4PAS at
[mG][mG][mA][mU][mU][mU][mU][mA][mA][mU][mA][mU][mA][mU][
PS

PAS single

mC]
NPASO -5

mismatch

This study

SV40PAS

This study

[mG][mU][mU][mA][mA][mC][dT][dT][dG][dT][dT][dT][dA][dT][mU][
PS
NPASO -6

mG][mC][mA][mG][mC]

ASO
[mG][mU][mA][mU][mC][mU][dA][dC][dT][dG][dG][dT][dT][dC][mG][
PS

Control

mU][mA][mU][mA][mU]
NPASO -7
NPASO - 8

GTTAACTTGTTTATTGCAGC

PS

Long

This study

SV40PAS

This study

ASO
GTATCTACTGGTTCGTATAT

PS

Control
Long

NPASO - 9
[mA][mG][mG][mG][mG][mG][dC][dA][dT][dT][dT][dT][dA][dA][mU][

This study

Dux4PAS at
PS

NPASO - 10

mA][mU][mA][mU][mC]

PAS

This study
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[mC][mU][mA][mG][mG][mU][mU][mC][mA][mG][mU][mC][mU][mA]

Dux4PAS at
PS

NPASO - 12

[mC]

~+160

[mA][mC][mA][mU][mA][mU][mC][mU][mC][mU][mA][mC][mA][mC][

Dux4PAS

This study

PS
NPASO - 13

mU][mG]

at~+200

[mU][mC][mU][mA][dG][dG][dT][dT][dC][dA][dG][dT][mC][mU][mA][

This study

Dux4PAS
PS

NPASO - 14

mC][mU]

at~+160

This study

Dux4PAS at
[mG][mC][mA][mA][mA][mU][mC][mU][mU][mC][mU][mA][mU][mA][
PS

Cleavage

mG]
site

NPASO - 15

This study

Dux4PAS
[mC][mU][mA][mU][mA][mG][mG][mA][mU][mC][mC][mA][mC][mA][
PS

Cleavage

mG]
site

NPASO - 16
[mA][mG][mG][mG][mG][dG][dC][dA][dT][dT][dT][dT][dA][dA][dT][m

This study

Dux4PAS at
PS

NPASO - 21

A][mU][mA][mU][mC]

PAS

[mA][mG][mG][mG][mG][mG][mC][mA][mU][mU][mU][mU][mA][mA]

This study

Dux4PAS at
PS, PO

NPASO - 22

[mU][mA][mU][mA][mU][mC]

PAS

This study
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Dux4 Exon
[mU][mG][mC][mG][mC][mG][mC][mA][mG][mG][mU][mC][mU][mA
NPASO - 23

PS, PO

3 Splice

][mG][mC][mC][mA][mG][mG]
Acceptor
[mU][mG][mU][mA][mA][mC][mC][mA][mU][mU][mC][mU][mC][mU]
NPASO - 24

This study

Dux4PAS
PS, PO

[mA][mG][mG][mU][mU][mC]

~160

[mC][mC][mU][mA][mA][mG][mU][mG][mA][mU][mG][mU][mA][mA]
NPASO - 25

This study

Dux4PAS
PS, PO

[mC][mC][mA][mU][mU][mC]

~160

[mC][mU][mA][mC][mA][mC][mU][mG][mA][mU][mC][mA][mC][mC][
NPASO - 26

This study

Dux4PAS
PS, PO

mU][mA][mA][mG][mU][mG]

~200

[mC][mG][mA][mG][mA][mA][mU][mU][mU][mU][mA][mA][mC][mA][
NPASO - 27

This study

Dux4PAS
PS, PO

mU][mA][mU][mC][mU][mC]

~200

This study

Dicer
Gapmer1 5[mG][mC][mU][mG][mA][dC][dC][dT][dT][dT][dT][dT][dG][dC][dT][m
PS

10-5

U][mC][mU][mC][mA]
NPASO-

Positive

(Lim et al.,

Dicer1A1

Control

2015)
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Dicer
Gapmer1 5[mA][mG][mG][mA][mG][dG][dA][dA][dG][dC][dC][dA][dA][dT][dT][
PS

10-5

mC][mA][mC][mA][mG]
NPASO-

Positive

(Lim et al.,

Dicer1B1

Control

2015)

Dicer
[mA][mG][mA][mC][mG][dA][dT][dA][dA][dC][dT][dT][dT][dA][dT][m

Gapmer
PS

NPASO-

U][mG][mG][mA][mG]

PAS
Targeting

Dicer1C1

This study

Dicer PAS
[mA][mG][mA][mC][mG][mA][mU][mA][mA][mC][mU][mU][mU][mA][
NPASO-

PS

Targeting

mu][mU][mG][mG][mA][mG]
Dicer1C2

non-gapmer
[mU][mA][mU][mC][mU][mC][mU][mA][mC][mA][mC][mU][mG][mA][

NPASO - 28

This study

Dux4PAS
PS

mU][mC]

~200

[mG][mA][mU][mC][mA][mC][mC][mU][mA][mA][mG][mU][mG][mA]
NPASO - 29

This study

Dux4PAS
PS

[mU][mG]

~200

This study
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[mC][mA][mU][mC][mU][mG][mC][mA][mC][mU][mG][mA][mU][mC]
NPASO - 30

Dux4PAS
PS

[mA][mC][mC][mG]

~120

NPASO-

[mU][mC][mA][mA][mC][dT][dT][dT][dA][dT][dT][dG][dT][dG][dG][m

Integrator4

INTS4-1

A][mC][mA][mG][mG]

NPASO-

[mU][mC][mA][mA][mC][mU][mU][mU][mA][mU][mU][mG][mU][mG]

This study

PS
PAS

This study

Integrator4
PS

INTS4-2

[mG][mA][mC][mA][mG][mG]

PAS

NPASO -

[mG][mG][mC][mA][mU][mU][mU][mU][mA][mA][mU][mA][mU][mA][

Dux4PAS at

4+22

mU][mC][mU][mC][mU][mG][mA][mA][mC]

PS, PO

PAS

This study

This study

Dux4PAS at
NPASO [mG][mC][mA][mA][mA][mU][mC][mU][mU][mC][mU][mA][mU][mA][

Cleavage

15+16
mG][mG][mA][mU][mC][mC][mA][mC][mA]

PS, PO

site

This study

Dux4PAS at
NPASO -

[mA][mA][mG][mU][mG][mG][mA][mA][mA][mU][mG][mU][mG][mU]

22MS

[mU][mA][mU][mC][mU][mC]

PO

PAS with
mismatch

This study
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Plasmid transfections
To prepare DNA for transfection, 0.1 -1.0 µg of DNA was mixed with 50µL of
OptiMEM. 0.5-2µL Lipofectamine 2000 was mixed with 50µL of OptiMEM and incubated
seven minutes, after which the DNA diluted in OptiMEM was mixed with Lipofectamine
Reagent diluted in OptiMEM. Lipid DNA complexes were allowed to for during a 25-minute
incubation at room temperature. The lipid:DNA complexes were then added to cells.

Microscopy

Cell Fixation and Fluorescence Microscopy.
15Abic CT#24 cells were plated at 25000cells/cm2. Cells were transfected with
fluorescein tagged ASO (ASO-2F) at concentrations 2.5 µM, 2 µM, 1.5 µM, 1 µM, 500 nM
and 100 nM using Lipofectamine 2000. 24 hrs after transfection cells were shifted to
differentiation medium (DM). Day 3 after switch to DM cells were washed once with
phosphate buffered saline (PBS), and then fixed with 4% paraformaldehyde (Electron
Microscopy Sciences, Pennsylvania USA) for 10 minutes. Cells were washed once with PBS
and nuclei were stained with a solution of 1:10000 4',6-diamidino-2-phenylindole (DAPI) in
PBS for 10 minutes at 37 ˚C. After DAPI staining, cells were washed twice with PBS and
visualized with the Leica DM IL LED Fluorescence Microscope.
Alternatively, cells were visualized without DAPI staining, and bright field/phase
contrast and GFP fluorescence images were taken of live cells.
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Western Blotting and Immunoprecipitation

General Cell Lysis
HEK293T cells were lysed in low salt lysis buffer (150mM NaCl, 100mM Tris pH 7.5,
1%NP-40). Patient cell lines and HeLa cells were lysed in high salt lysis buffer (500mM
NaCl, 100mM Tris pH 7.5, 1%NP-40). Patient cell lines and RD cells were lysed in RIPA
buffer (50mM Tris pH 8, 150mM NaCl, 1% NP-40, 0.5% Sodium Deoxycholate, and 0.1%
sodium dodecyl sulfate (SDS)). All cells were washed once with PBS and then incubated
with rocking at 4˚C for 15 minutes with appropriate lysis buffer. Cell lysis was completed with
one round of freeze-thaw. Protein centration of either low- or high-Salt lysed cells was
quantified using the Bradford assay and 10µg-20µg of cell lysate was loaded and resolved
using either a 10% or 12.5 %SDS-PAGE. Protein samples were prepared in 4X SDS loading
buffer (200mM Tris pH 6.8, 0.8%SDS, 20% glycerol, 400mM Dithiothreitol) and boiled for
5mins at 95˚C prior to loading on SDS-PAGE.

Immunoprecipitation of Dux4
Protein G Dynabeads (Thermo Fisher Scientific) was washed twice with Phosphate
Buffered Saline with Tween 20 (PBS-T), and once with RIPA buffer. Beads were then bound
to 10mg of mAB raised to Dux4 in PBS-T, by rotating 10 minutes at room temperature,
followed by 1hr at 4˚C. After antibody adsorption to the beads, the supernatant was
removed and beads were resuspended in 100µL of PBS-T. Immortalized human myoblasts
and myotubes in grown on 35mm dishes were washed once with PBS and were then lysed
with 500µL of RIPA buffer. 400µL of RIPA lysate of was added to the 20µL of mAB Dux4
labelled beads. The slurry was rotated overnight at 4˚C. The supernatant was removed and
cells were washed once with RIPA buffer, and twice with PBS-T. To elute the protein bound
to the beads, after removal of PBS-T at final wash, beads were resuspended in 0.1M
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Glycine pH 2.7. To which, equal volume of 2X Laemilli buffer (Biorad) was added. After
boiling the sample for 5 minutes, the sample was resolved using SDS-PAGE.

Electrophoresis and Immunoblotting
For all SDS-PAGE experiments, lysates were initially resolved using 90V through the
stacking gel, and then the voltage was increase to 140V and the gel was run until the 17kDa
marker (PageRuler Plus Prestained Marker, Thermo Fisher Scientific) ran off the gel. The
proteins were transferred to PVDF membrane. The membrane was blocked 20 minutes in
5% milk PBS-T, then incubated with primary antibody diluted in 5%milk PBS-T for 1hr with
rocking at room temperature or overnight with rocking at 4˚C. After three, 10-minute washes
with 5%milk PBS-T, the membrane was incubated 1hr with 1:5000 dilution of secondary
antibody in 5% milk PBS-T. Membrane was washed thrice for 10 minutes each, then rinsed
once with PBS. The membrane was then incubated for 5 minutes with 4-IBPA ECL.
Chemiluminescent signal was visualized by exposing film in autoradiograph cassette or with
the Bio-Rad ChemiDoc Touch Imaging System. Western blots were quantified using Image
J software (imagej.nih.gov/ij/) or Image Lab (Biorad).

Antibodies
Primary antibodies used in this project were: mouse αGFP, JL-8 (632380, Clontech,
California USA), mouse αCherry, 1C51 (ab125096, Abcam, Massachusetts, USA), mouse αGAPDH (AM4300, Thermo Fisher Scientific), HRP conjugated αHA (A190-107P, Bethyl,
Texas, USA), HRP Conjugated αFlag-M2 (A8592, Sigma), mouse α-Flag-M2 (A9469,
Sigma), rabbit α-Exosc4 (A303-774A, Bethyl), mouse α-MHC (MAB4470, R&D Systems,
Minnesota, USA), mouse α-Dux4, 9A12 (MABD116, Millipore, California USA), rabbit
αDux4, E55 (ab124699, Abcam), rabbit α-Tubulin (ab15246, Abcam), and α-myc.
Secondary antibodies were Horse Radish Peroxidase conjugated α mouse (715-053-150,
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Jackson Immuno Research, Pennsylvania, USA), and Horse Radish Peroxidase conjugated
α rabbit (NA934V, GE Healthcare, Buckinghamshire, UK)

Plate Reader Assays

Luciferase Assay
HEK293T cells or RD cells were seeded in a 24 well plate at 1.25x105 and 3.5 x104
cells/well respectively. The following day, the cells were transfected with 100 ng of
psiCheck2 reporter plasmid using Lipofectamine 2000 as described above. 48 hrs after
transfection cells were lysed in passive lysis buffer (Promega) for 15 minutes at room
temperature. Firefly and Renilla luciferase activities were determined using the Dual
Luciferase Reporter Assay System (Promega) in the Enspire 2300 Multilabel Reader.
Renilla luciferase activity was normalized to Firefly luciferase activity.

Fluorescence Plate Reader Assay
HeLa cells were seeded in a 24 well plate at 8.5x104 cells/well. HEK293T cells were
seeded in a 96 well plate at 1.3x104 cells/well. The following days, cells were transfected
with 500ng or 100ng of reporter plasmid, with 100 or 20 ng of transfection control plasmid
using Lipofectamine 2000 as described above. Fluorescence intensity was measure at 24 or
48 hrs post-transfection in the Enspire 2300 Multilabel Reader or the Tecan Infinite 200 Pro
Plate Reader. Excitation and emission wavelengths of eGFP was selected as 488/509 and
the excitation and emission wavelengths of mCherry selected was 575/610.
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Nucleic Acid Preparation Analysis and Methodology:

Total RNA Extraction
RNA was extracted from cells using TriZol Reagent (Thermo Fisher Scientific).
Briefly, cells were incubated with rocking for 15 minutes at room temperature with TriZol.
Chloroform was added to the TriZol reagent and the mixture was vortexed 10 seconds. The
samples were incubated for 10 minutes on ice, then centrifuged at 4˚C for 20 minutes at
15,000rpm. The aqueous layer was mixed with isopropanol and 10 µg glycogen (AM9510,
Thermo Fisher Scientific), and incubated overnight at -20˚C or 30 minutes at -80˚C. The
samples were then centrifuged at 15,000 rpm for 20 minutes at 4˚C. The isopropanol was
removed without disturbing the RNA pellet, and the pellet was washed once with 75%
ethanol. The samples were centrifuged at 4˚C for 20 minutes at 15000rpm and then the
ethanol was removed. After drying, the pellet was resuspended in 30µL of DEPC treated
water (Thermo Fisher Scientific).

Complementary DNA (cDNA) synthesis
RNA for RT-PCR and qPCR were DNAse treated as follows. Briefly, 3 – 10ug of
RNA was treated with Turbo DNAse (Thermo Fisher Scientific) for 30 minutes at 37˚C. After
the 30 minutes elapsed the DNAse was inactivated with the addition of Turbo DNAse
inactivation buffer, and the mixture was incubated 10 minutes at 25˚C with agitation.
Following the incubation, the mixture was briefly centrifuged to pellet the DNAse. 1 µg of
DNAse treated RNA was used for cDNA synthesis with M-MLV Reverse Transcriptase
(Thermo Fisher Scientific). Reverse transcription reaction was allowed to proceed for 1hr at
37°C, followed by incubation at 95°C for 5 minutess. In the event, where RNA from
myoblasts was being prepared to assay Dux4 mRNA expression, 2 – 3 µg of DNAse treated
RNA was used for cDNA synthesis with Superscript III Reverse Transcriptase (Thermo
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Fisher Scientific). cDNA synthesis for RT PCR and qPCR were primed with OligodT12-18,
OligodT20 (Thermo Fisher Scientific), or OligodT18 (New England Biolabs). cDNA for 3′ RACE
was primed with SP6 OligodT or T7 OligodT.

Rapid Amplification of Complementary DNA Ends (RACE)
Primers used for 3′RACE are listed in Table 3.6. The polyadenylated cDNA pool was
subjected to two consecutive rounds of PCR at 20 cycles each to amplify the 3′ RACE
product. 1µL of cDNA was used as template for the 1st cycle of PCR, with Pfu polymerase,
primed with appropriate forward primer and SP6 OligodT or T7 OligodT, as reverse primer in
a 50µL reaction. The cycling conditions are 95˚C for 3 minutes, 20 cycles of 95˚C for 30s,
55˚C for 30s, 72˚C for 30s, and final elongation at 72˚C for 5minutes. After the 1st PCR
cycle, 5 µL of PCR product was run on 1-3% agarose gel. 2 µL of the product from the 1st
PCR cycle, was used as template for a second round of PCR, using cycling conditions as
above. After 2nd round of PCR, 5 uL of the PCR product was run on 1-3% agarose gel. To
determine the site of polyadenylation, 20 µL of the final PCR product was run on 1%
agarose gel and bands were excised and purified and submitted for sequencing (Genewiz,
NJ USA or Lonestar Labs, TX USA with a nested primer. Alternatively, 4 µL of the PCR
product was ligated to the Zero Blunt Topo PCR Vector (Thermo Fisher Scientific) according
to manufacturer’s recommendation. XL1-Blue competent cells were transformed with 1 µL of
the ligation reaction and plated on Luria Broth-Kanamycin Agar plates. Amplified clones that
contained inserts as determined by EcoRI restriction digest screen were submitted for
sequencing with M13F and M13R primers.

RT-PCR
Primers used for RT-PCR are listed in Table 3.6. 2 µL of cDNA was used as
template for PCR with Pfu polymerase. The final PCR product was run on 2-3% agarose gel.
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PCR products were ligated and transformed as described above, and clones amplified were
submitted for sequencing as above.

qPCR
Primers used for qPCR are listed in Table 3.6. 2 µL of the undiluted cDNA was used
in the reaction with SYBR Green master mix (KAPA Biosystems or Biorad) and appropriate
primers. Data were acquired using the Stratagene Agilient MX3000P or Biorad CFX
Connect, and calculated using ΔΔCT method.
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Table 3.6. Table of DNA Oligonucleotides for PCR
Name

Sequence

Purpose

SP6 3'RACE R1

GGCCGGATTTAGGTGACACTATAGTTTTTTTTTTTTT

3′RACE Reverse primer

TTTTTTTTTTTT
SP6 3'RACE R2

CCGGATTTAGGTGACACTATAG

3′RACE Reverse primer

TSS F1

CCCACTGCTTACTGGCTTATCG

3′RACE Transcription Start Site PASGFP
Reporter

TSS F2

CGAAATTAATACGACTCAC

3′RACE Transcription Start Site PASGFP
Reporter

TSS F3

GACCCAAGCTGGCTAGCG

3′RACE Transcription Start Site PASGFP
Reporter

mCHE-ORF F1

CTTCAAGTGGGAGCGCGTG

3′RACE, qRT-PCR: mCherry ORF

mCHE-ORF F2

GGCGAGTTCATCTACAAGGTG

3′RACE, qRT-PCR: mCherry ORF

mCHE-ORF F3

GCCTCCTCCGAGCGGATG

3′RACE pCCHAM Reporter mCherry ORF

mCHE-ORF F4

GTCAACATCAAGCTGGACATC

3′RACE pCCHAM Reporter mCherry ORF

mCHE-R1

GCTTCAGCCTCTGCTTGATCTC

qRT-PCR: mCherry ORF
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T7 3'RACE R1

GGCCGGTAATACGACTCACTATAGTTTTTTTTTTTTT

3′RACE Reverse primer

TTTTTTTTTTTT
T7 R2

GGCCGGTAATACGACTCACTATAG

3′RACE Reverse primer

NRO-G4A

TGAGCAAGGGCGAGGAGCTGTT

qRT-PCR, RTPCR: GFP ORF, Forward

NRO-G4B

AAGCACTGCACGCCGTAGGTCA

qRT-PCR, RTPCR: GFP ORF, Reverse

NRO-G5A

GGGCATCGACTTCAAGGAGGAC

qRT-PCR, RTPCR: GFP ORF, Forward

NRO-G5B

ACGCTGCCGTCCTCGATGTT

qRT-PCR, RTPCR: GFP ORF, Reverse

NRO-NeoF

ATTCGGCTATGACTGGGCAC

qRT-PCR: Neomycin Resistance Gene ORF

NRO-NeoR

CCAATAGCAGCCAGTCCCTT

qRT-PCR: Neomycin Resistance Gene ORF

eGFP RACE 3

GGATCACTCTCGGCATGG

3′RACE: GFP ORF

eGFP RACE 2

GATCACATGGTCCTGCTGGAG

3′RACE: GFP ORF

eGFP RACE 1

GACAAGCAGAAGAACGGCATC

3′RACE: GFP ORF

NeoF2

TCGTGCTTTACGGTATCGCC

RTPCR: Neomycin Resistance Gene ORF

NeoR2

GGCGAAGAACTCCAGCATGA

RTPCR: Neomycin Resistance Gene ORF

N0143

GGCAAGCTGACCCTGAAGTT

qRT-PCR; GFP ORF, Forward

89

N0144

GGTCTTGTAGTTGCCGTCGT

qRT-PCR; GFP ORF, Reverse

GAPDH F

CAG GAG GCA TTG CTG ATG AT

qRT-PCR, RTPCR

GAPDH R

GAA GGC TGG GGC TCA TTT

qRT-PCR, RTPCR

B-GUSF

GAAAATATGTGGTTGGAGAGCTCATT

qRT-PCR, RTPCR

B-GUSR

CCGAGTGAAGATCCCCTTTTTA

qRT-PCR, RTPCR

18S F

CAGCCACCCGAGATTGAGCA

qRT-PCR

18S R

TAGTAGCGACGGGCGGTGTG

qRT-PCR

ROCK1P1 F

ACACTCTACCACTTTCCTGCCA

qRT-PCR, RTPCR

ROCK1P1 R

TGTGGCACTTAACATGGCGTCT

qRT-PCR, RTPCR

N0D64

GTGAGCAAGGGCGAGGAGC

qRT-PCR: GFP ORF, Forward

N0D67

GGTCAGCTTGCCGTAGGTGG

qRT-PCR: GFP ORF, Reverse

N0129

GGACTTGAAGAAGTCGTGCTGC

qRT-PCR: GFP w/intron Exon-Exon Junction,
Forward

N0130

GAG GGC GAT GCC ACC TAC

qRT-PCR: GFP ORF, Reverse

N0157

CATGGTAACGCTGCCTCCAG

RTPCR: Luciferase, Forward

90

N0158

GGCGATATGAGCCATTCCCG

RTPCR: Luciferase, Reverse

N0159

TCGAGCTGCTGAACCTTCCA

RTPCR: Luciferase, Forward

N0160

CGATCACGTCCACGACACTC

RTPCR: Luciferase, Reverse

N0161

TAGACGGCCTACCCTCTCCT

RTPCR: Luciferase, Forward

N0162

CCAGGGTCGGACTCGATGAA

RTPCR: Luciferase, Reverse

N0163

CCTGGGCTACCTGATTTGCG

RTPCR: Luciferase, Forward

N0164

GAAGCTGAACAGGGTTGGCA

RTPCR: Luciferase, Reverse

N0165

GCCGAGCTGGAGTCTATCCT

RTPCR: Luciferase, Forward

N0166

TCATGGTCTTGCCGTGTTCC

RTPCR: Luciferase, Reverse

N0167

TTCACCGATGCCCACATTGA

RTPCR: Luciferase, Forward

N0168

GTTCTCAGAGCACACCACGA

RTPCR: Luciferase, Reverse

NO169

CAGCGACGATCTGCCTAAGA

RTPCR: Luciferase, Forward

NO170

TCCAACGCTATTGTCGAGGG

RTPCR: Luciferase, Forward

NO171

ATCAAGAGCTTCGTGGAGCG

RTPCR: Luciferase, Forward

NO172

ACCGAGTTCGTGAAGGTGAAG

RTPCR: Luciferase, Forward
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NO173

ACGCTCCAGATGAAATGGGT

RTPCR: Luciferase, Forward

NO174

CGTGCTGAAGAACGAGCAGT

RTPCR: Luciferase, Forward

WO851

GTTTACGTCGCCGTCCAGCTC

qRT-PCR; GFP ORF, Reverse

N0D103(RACE)

AGGCGCAACCTCTCCTAGAAAC

3' RACE: Dux4 Exon 1 C-terminus

N0D104(RACE)

GAAGCACCCCTCAGCGAGGAA

3' RACE: Dux4 Exon 1 C-terminus

N0D105(RACE)

GGCTCTGCTGGAGGAGCTTTAG

3' RACE: Dux4 Exon 1 C-terminus

NOD199

CCAGGAGATGTAACTCTAATCCAGGTTTGC

RTPCR: Dux4 Exon 3, Reverse

NOD200

GCTGGAAGCACCCCTCAGCGAGGAA

RTPCR: Dux4 Exon 1 C-terminus, Forward

NOD201

GAGCTCCTGGCGAGCCCGGAGTTTCTG

RTPCR: Dux4 Exon 1 C-terminus, Forward

NOD202

GGCCCGGTGAGAGACTCCACAC

RTPCR: Dux4 Exon 2, Forward

NOD203

GGCCCGGTGAGAGACTCCACA

RTPCR: Dux4 Exon 2, Forward

NOD204

GCGCACCCCGGCTGACGTGCAA

RTPCR: Dux4 Exon 3, Forward

NOD205

GTAACTCTAATCCAGGTTTGCCTAGACAGC

RTPCR: Dux4 Exon 3, Reverse

NOD206

CCCCGAGCCAAAGCGAGGCCCTGCGAGCCT

RTPCR: Dux4 Exon 1 N-terminus, Forward

NOD207

CGGCCCTGGCCCGGGAGACGCGGCCCGC

RTPCR: Dux4 Exon 1 N-terminus, Forward
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NOD208A

CCTGGTCTGCACTCCCCT

qRT-PCR, RTPCR: Dux4 Exon1 C-terminus,
Forward

NOD208B

CTAAAGCTCCTCCAGCAGAGCC

qRT-PCR, RTPCR: Dux4 Exon1 C-terminus,
Reverse

NOD208C

GAGCCCGGTATTCTTCCTCG

qRT-PCR, RTPCR: Dux4 Exon1 C-terminus,
Reverse

NOD208Anest

GGCGCAACCTCTCCTAGAAA

RTPCR: Dux4 Exon 1 C-terminus, Forward

NOD208Bnest

GAGCCCGGTATTCTTCCTCG

RTPCR: Dux4 Exon 1 C-terminus, Reverse

NOD209A

GCTTTCGTGAGCCAGGCAGCG

RTPCR: Dux4 Exon 1 C-terminus, Forward

NOD209B

CTTGAGCGGGCCCAGGCTGTG

RTPCR: Dux4 Exon 1 C-terminus, Reverse

NOD210A

TCCCAGGGGAGTCCGTG

RTPCR: Dux4 Exon 1 C-terminus, Forward

NOD210B

TTTCTAGGAGAGGTTGCGCC

RTPCR: Dux4 Exon 1 C-terminus, Reverse

NOD211A

CTGGTCTGCACTCCCCTG

RTPCR: Dux4 Exon 1 C-terminus, Forward

NOD211B

CGTCCTAAAGCTCCTCCAGC

RTPCR: Dux4 Exon 1 C-terminus, Reverse

NOD212

GTCTAGGCCCGGTGAGAGAC

RTPCR: Dux4 Exon 2, Forward

NOD213

ATCCACAGGGAGGGGGCATTTTAATATATC

RTPCR: Dux4 Exon 3, Reverse
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NOD229

GCTGGTACCTGGGCCG

RTPCR: Dux4 Exon 2, Reverse

NOD230

CTAGGCCCGGTGAGAGACT

RTPCR: Dux4 Exon 2, Forward

NOD231

GGTTTGCCTAGACAGCGTCG

RTPCR: Dux4 Exon 3, Reverse

NOD232

CGTAGCCAGCCAGGTGTTC

RTPCR: Dux4 Intron 1, Reverse

NOD233

AAGGCAGGAATCCCAGGC

RTPCR: Dux4 Intron 1, Reverse

NOD236

GAAAGGCAGTTCTCCGCGG

RTPCR: Dux4 Exon 2, Reverse

Dicer1 Common F

CTCATTATGACTTGCTATGTCGCCTTG

qRT-PCR

Dicer1 Common R

CACAATCTCACATGGCTGAGAAG

qRT-PCR

Dicer1 Distal F

TGCTTTCCGCAGTCCTAACTATG

qRT-PCR

Dicer1 Distal R

AATGCCACAGACAAAAATGACC

qRT-PCR

PRAMEF1

Biorad, PrimePCR SYBR Green: qHsaCED0057477

qRT-PCR, primer pair

TRIM43

Biorad, PrimePCR SYBR Green: qHsaCID0038709

qRT-PCR, primer pair

TRIM48

Biorad, PrimePCR SYBR Green: qHsaCID0022430

qRT-PCR, primer pair

TRIM49

Biorad, PrimePCR SYBR Green: qHsaCED0046590

qRT-PCR, primer pair

ZSCAN4

Biorad, PrimePCR SYBR Green: qHsaCID0036861

qRT-PCR, primer pair
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Genomic DNA Extraction
Genomic DNA was extracted from cells using the Rapid Genomic DNA Extraction
(RGDE) method (Ali et al., 2008).
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Chapter 4 : Development of Tools to Assay mRNA 3’end processing in cells

This chapter is based in part upon Peart N, Wagner EJ. 2016. Gain-of-function
reporters for analysis of mRNA 3′ end formation: Design and Optimization. BioTechniques
60:137-140. doi 10.2144/000114390
© 2009 BioTechniques. Used by Permission
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Development of Tools to Assay mRNA 3′ end processing in cells.
Introduction
The formation of the 3′ end of mRNA is a complex and highly regulated process that
is essential for the generation of mature mRNA (Chan et al., 2011). In eukaryotic cells, the
process involves the recognition of cis sequence elements by several trans-acting protein
factors (Mandel et al., 2008). A key cis element essential for this process is the
hexanucleotide polyadenylation signal (PAS). The recognition of the PAS, typically
AAUAAA, is aided by the presence of other cis sequence elements to stimulate cleavage
and subsequent polyadenylation of the mRNA. These other sequences may include a
loosely defined upstream sequence element (USE), a G/U-rich or G-rich downstream
sequence element (DSE), and the actual cleavage site itself (Tian and Graber, 2012). The
combination of these cis regulatory elements creates a biosynthetic context that determines
whether an mRNA will be efficiently processed (Hu et al., 2005; Tian and Graber, 2012;
Wilusz et al., 1990). Perturbation of this context is evident in the etiologies of a variety of
human diseases (Danckwardt et al., 2008).

Gain of Function Reporter
Cell-based reporters can be used to analyze mutations in disease-causing genes for
their effect on mRNA 3′ end formation, as well as to understand the biological mechanism of
3′ end formation. Reporter systems have been successfully used to study the requirements
of various RNA 3′ end formation, including the Nrd1/Nab3/Sen2 complex in Saccharomyces
cerevisiae transcription termination (Steinmetz et al., 2001), the cis and trans requirements
of histone mRNA 3′ end formation (Yang et al., 2009), the role of the Integrator complex in
snRNA 3′ end formation (Albrecht and Wagner, 2012; Chen et al., 2013a), and more
recently to investigate effects of the nuclear cap binding complex on stimulation of 3′ end
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processing of several RNA families (Hallais et al., 2013). In the case of snRNA or histone
pre-mRNA processing the cis-acting signals are compact making reporter design
straightforward, however, the processing signals required for cleavage and polyadenylation
are much more diverse and cover larger ranges (Hu et al., 2005). Here, we describe the
construction of an effective, gain-of-function reporter system to analyze pre-mRNA
processing and provide an assessment of the reporter’s capabilities and limitations.
To demonstrate the design and utility of a GFP expression-based assay to monitor
mRNA 3′ end processing, we generated a transcriptional read-through reporter (Figure
4.1A). This reporter (termed PAS-GFP) is constructed in the pcDNA3.1 (+) vector (Thermo
Fisher Scientific) where sequences to be analyzed are cloned upstream of a GFP open
reading frame (ORF), which itself is followed by a bovine growth hormone PAS. The
expectation is that if RNAPII encounters a functional cleavage and polyadenylation signal
prior to transcription of GFP-encoding mRNA, no fluorescence will be observed. As a
positive control, we tested the late SV40 PAS, which has been well-characterized for
cleavage and polyadenylation efficiency (Zarkower and Wickens, 1988). Into the PAS-GFP
reporter, we inserted a 233-nt-long sequence that included the SV40 PAS, cleavage site,
and a DSE. Importantly, we also created two negative control reporters where random
sequences devoid of defined cleavage and polyadenylation elements were inserted
upstream of the GFP ORF (Figure 4.1A). All reporter constructs as well as an empty PASGFP were each transiently transfected into HeLa or HEK293T cells and both protein and
total RNA were isolated for analysis 48 hrs post-transfection (as described in (Albrecht and
Wagner, 2012; Chen et al., 2013a)). An additional plasmid encoding HA-tagged mCherry
was co-transfected to control for transfection efficiency. We observed that only the insertion
of the SV40 PAS into the reporter prevented the expression of the GFP protein (Figure
4.1B). Quantification of the GFP expression using ImageJ analysis correlated with qRT-PCR
measurement of GFP mRNA (Figure 4.1C/D). It is noteworthy that both random sequences
98

slightly reduced the expression of the GFP reporter compared to the empty PAS-GFP
vector. This is not surprising as some level of translation inhibition would be expected from
placement of a ~220nt insertion upstream of the GFP start codon. Along the same lines, it
is important to consider that not all random sequences are “inert” and may contain cryptic
regulatory elements therefore it is recommended to test multiple negative control
sequences.
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Figure 4.1. PAS-GFP reporter analysis using an SV40 polyadenylation signal (PAS). (A)
Schematic of the transcriptional read-through reporter designed to study mRNA 3´-end
formation. The GFP open reading frame (ORF) without a native AUG start codon is placed
downstream of either the SV40 PAS (SV40-GFP) or random sequences derived from the
pUC vector (RSeq-GFP). (B) Western blot of lysates from HeLa cells (left) and HEK293T
cells (right) transfected with the reporters shown in panel A. The Western blots were probed
for GFP protein using αGFP. HAmCherry protein expressed from a co-transfected
HAmCherry plasmid used to normalize transfection was probed with αHA, and tubulin used
as a loading control was probed with α-tub. These controls were used in all blots throughout
this study. (C) Quantification of the GFP signal in the Western blot of the HeLa lysates
shown in panel B (left) was performed using Image J. (D) qRT-PCR analysis of RNA
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isolated from the HeLa cells transfected as those analyzed by Western blotting in panel B
(left). Error bars show standard deviation from three independent experiments.

101

To demonstrate sensitivity of the reporter to mutations of the cis regulatory element
of 3′ end processing, we introduced a three-nucleotide mutation (AAUAAA to GGGAAA) of
the PAS (PAS null [PN]), and deletion of the DSE (DSE null [DN]) or a mutation of the
cleavage site (cleavage null [CN]) (Figure 4.2A) The most significant read-through was
observed after mutation of the PAS and to a lesser extent the DSE (Figure 4.2B). It was not
unexpected that the cleavage site mutation did not result in significant read-through as this
is thought to be the least critical element, as alternative cleavage sites can be utilized if one
is mutated (Tian and Graber, 2012). Importantly, we observed strong correlation between
GFP protein expression and GFP mRNA levels demonstrating that GFP expression is
reflective of mRNA production (Figure 4.2C/D). Finally, 3′ RACE and sequencing confirmed
that the SV40 PAS located upstream of GFP or the BGH PAS located downstream of GFP
represent the only two cleavage and polyadenylation events as predicted (Figure 4.2E). Our
data show that while monitoring GFP expression is representative of transcriptional readthrough, we did observe slightly greater sensitivity measuring read-through using qRT-PCR
analysis, where we measured the GFP mRNA levels normalized to the neomycin resistance
mRNA encoded elsewhere within the PAS-GFP plasmid.
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Figure 4.2 Effect of start codon context on polyadenylation signal (PAS)-GFP reporter
analysis. (A) Schematic of SV40 mutant GFP reporter constructs with mutations of the PAS
from AUAAAA to GGGAAA (PN), deletion of the downstream sequence element (DSE)
(DN), and mutation of the cleavage site from CA to CG (CN). (B) Western blot of lysates
from HeLa cells (left) and HEK293T cells (right) transfected with the reporters shown in
panel A. (C) Quantification of the GFP signal in the Western blot of the HeLa lysates shown
in panel B (left) performed using Image J. (D) qRT-PCR analysis of RNA isolated from the
HeLa cells transfected with the reporters shown in panel A. Error bars show standard
deviation from three independent experiments. (E) Ethidium bromide–stained agarose gel
(top) showing products of 3´ rapid amplification of cDNA ends (RACE) of RNA isolated from
HeLa cells transfected with the reporters shown in panel A. Sequence chromatogram
(bottom) obtained by 3´ RACE showing that the SV40 PAS in the reporter uses the cleavage
site previously reported in the literature. (F) Schematic of the transcriptional read-through
reporter designed to study mRNA 3´-end formation. The GFP open reading frame (ORF)
with a native AUG start codon was placed downstream of the SV40 PAS constructs. (G)
Western blot of lysates from HeLa cells transfected with reporter constructs containing the
SV40 PASs shown in panel A placed into the reporter plasmid with the native AUG start
codon of GFP shown in panel F.
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One possible concern for a transcriptional read-through reporter with large inserts
upstream is the location and context of the start codon. The constructs shown in (Figure
4.2A) all have the optimized GFP start codon mutated and rely on the start codon
fortuitously located within the SV40 polyadenylation signal. We redesigned the PAS-GFP
reporter, such that the EGFP ORF cloned downstream of NotI maintains its native AUG
(Figure 4.2F). The same SV40PAS and its mutants were then tested in this new context to
determine if the presence of an optimal codon would alter the results. While we did not
detect any difference in the effects of the SV40 mutants, however, we did observe
preferential usage of the native AUG of the EGFP by Western Blot analysis (Figure 4.2G)
despite the presence of an upstream start codon. This is most likely because the NotI site
flanking the endogenous EGFP start codon is GC rich similar to a Kozak sequence.
Results from recent global analyses of altered RNA 3′ end formation events have
uncovered a process that is highly dynamic and subject to regulation ((Gruber et al., 2014;
Shepard et al., 2011; Xia et al., 2014), and reviewed in (Shi and Manley, 2015)). However,
these approaches must be followed up using specific reagents to provide mechanistic
understanding on how RNA processing takes place. Typical reporters used by others to
investigate mRNA 3′ end formation (Gehring et al., 2001; Mayr and Bartel, 2009) place the 3′
end processing elements downstream of a heterologous ORF (e.g. luciferase or

-globin)


and then either the protein or mRNA expression is measured. These reporters have proven
to be robust and the primary strength of this design compared to the transcriptional readthrough reporter described in this study is that 3′ end processing occurs in a more native
context, which is downstream of an ORF. However, the potential limitation of reporters with
3′ end-processing signals placed downstream lies in the interpretation of loss-of-function
events. Mutations that are introduced into these reporters that result in failure to produce the
reporter product may be confounded by other factors such as instability of the RNA
transcribed due altered 3′ UTR content. This concern is mitigated by the design of our
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transcriptional read-through reporters. However, the PAS-GFP reporter described here is
also not without limitation. As previously mentioned, cryptic regulatory elements in the 5′
UTR may impair reporter expression. We addressed one of these limitations by exploring
the importance of the start codon context (Figure 4.2). Additional considerations when
designing a transcriptional read-through reporter are the presence of upstream ORFs
(uORFs), secondary structures limiting start codon recognition, and the potential use of a
non-AUG start codon (Araujo et al., 2012; Ivanov et al., 2011). These factors may affect
translation of the downstream reporter. These constraints may also place an upper limit on
the size of the construct investigated.
Nonetheless, the customizable, gain-of-function PAS-GFP reporter described here
offers an immunological and visual output to allow for a case-by-case analysis of mRNA 3′
end formation. Moreover, this reporter is readily adaptable for more complicated model
systems including in vivo expression for tissue-specific analysis of mRNA 3′ end formation
and genome-wide CRISPR screening to identify novel regulatory factors.

Loss of Function Reporter
While we have alluded to the weakness within loss of function reporters for assaying
mRNA 3′ end processing in cells, these reporters are still a viable tool for assaying 3′ end
formation if used appropriately, and the data are interpreted with an understanding of the
reporter limitations. Here, we describe a loss of function reporter that addresses two
limitations of traditional loss-of-function reporters that assay case specific mRNA 3′end
formation in cells. The first limitation is the dependence upon radioactivity by means of
northern blot or cell lysis to monitor enzymatic activity of the reporter gene. Here, we use the
fluorescent mCherry as reporter. mCherry is a stable monomer with high brightness (Shaner
et al., 2004) compared to other fluorescent proteins. We can detect the reporter expression
using fluorescence intensity or by immunoblotting. The reporter is also amenable to analysis
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of the mRNA by qPCR. The second limitation for assaying 3′end formation using loss-offunction reporters lies in the failure to cleave and polyadenylate at the required downstream
PAS. Instead, the polymerase may skip over what it perceives as weak PAS and the
reporter may be subject to unintentional alternative cleavage and polyadenylation (APA). To
address this limitation downstream of the multiple cloning site into which the interrogated
PAS is cloned we placed the self -cleaving ribozyme Schistosoma Mansoni Hammerhead
(Martick et al., 2008). This reporter, termed pCCHAM (Figure 4.3A) is constructed in the
pUC19 vector. The CMV promoter was amplified and cloned in the EcoRI restriction site of
the pUC19 vector. We then cloned using annealed oligonucleotide, as described above, the
S. Mansoni Hammerhead, between PstI and HindIII. HA-tagged mCherry was amplified and
cloned into the KpnI and BamHI. Polyadenylation signals interrogated with this reporter were
cloned between BamHI and SalI. As a proof of principle, to investigate the utility of the
reporter, we cloned the late SV40PAS as described above. We also used site-directed
mutagenesis to generate PAS Null, Cleavage Null and DSE null SV40 constructs as
described previously in this study for the PAS-GFP Reporter (Figure 4.3A).
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Figure 4.3 pCCHam reporter analysis using an SV40 polyadenylation signal (PAS). A.
Schematic of the loss of function pCCHAM reporter designed to study mRNA 3′-end
formation. The mCherry open reading frame (ORF) is cloned in the pUC Vector, after a
cytomegalovirus (CMV) promoter, and the self-cleaving Hammerhead ribozyme (HH) is
placed in the 3′ terminus of the multiple cloning site of the vector. Random Sequence
(Random Seq or RSeq) derived from elsewhere in the pUC vector or SV40PAS sequences
are cloned between the stop codon of mCherry and the Hammerhead ribozyme. (B) qRTPCR analysis of RNA isolated from the HeLa cells transfected with pCCHAM SV40 or
pCCHAM without PAS (empty). Error bars show standard deviation from two independent
experiments. (C) Fluorescent plate reader analysis of HeLa cells transfected with pCCHAM
SV40, pCCHAM Empty, pCCHAM RSeq. Fluorescence intensity above background was
measured relative to untransfected cells, and normalized for transfection using GFP which
was co-transfected. (D) Fluorescent plate reader analysis (Top) of HeLa cells transfected
with the reporters shown in panel A. Percentage fluorescence intensity of relative to
pCCHAMSV40, and normalized for transfection using co-transfected GFP. Western blot
(Bottom) of lysates from HeLa cells. The Western blots were probed for HAmCherry protein
expressed with α-HA, and tubulin used as a loading control was probed with α-tub.
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The reporter was transiently transfected into HeLa cells and protein and RNA were
extracted from the cells 48 hrs post transfection. Prior to harvesting RNA or protein from the
cells, fluorescence intensity was determined for each construct. We demonstrate that we do
not detect reporter expression when there is no PAS, while the SV40 PAS placed
downstream of mCherry allows for robust reporter expression (Figure 4.3B/C). Furthermore,
we observe a reduction in the expression of the mCherry, when the hexanucleotide PAS is
mutated (PN), and the DSE is removed (Figure 4.3D The cleavage site (CN) mutant likely
does not show significant reduction due in part to the promiscuity in the cleavage site
selection (Pauws et al., 2001; Tian and Graber, 2012). On the other hand, in our PAS-GFP
reporter we still obtained a cleavage product using the CG dinucleotide as a cleavage site,
despite its suboptimality (Chen et al., 1995; Furger et al., 1998; Jin et al., 2005). Therefore,
these reporters may not be sensitive enough to measure the efficacy of CPA by impairing
the cleavage site, or further supports other data (Chen et al., 1995; Furger et al., 1998; Jin
et al., 2005) that favor promiscuity in the cleavage site selection.
Nevertheless, this reporter still possess the limitation that reporter output, is subject
to UTR destabilization unrelated to CPA, which can obfuscate the results. However, like
similar reporters this can be addressed by assaying the mRNA levels in conjunction with the
protein output. Nonetheless, it can be useful as a complement to the PAS-GFP reporter to
interrogate CPA in a more native context, provided validation in the PAS-GFP reporter
supports the interrogated element as a PAS.
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Chapter 5 : Exploring the 3′ end processing of Dux4 mRNA
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FSHD, a disease of the dysregulated 3′ end processing?
The importance of the context of the cis regulatory elements is evident in disease
pathology. Several human diseases can be attributed to dysregulation of 3′ end processing
of mRNA. Two common human diseases attributed to changes in cis regulatory elements
that result in disease include β-thalassemia and thrombophilia. Loss-of-function mutation
within the PAS of the β-globin gene decreases the efficiency of cleavage and
polyadenylation and thereby mRNA production, which consequently impairs accumulation of
the β-globin protein and leads to the development of β-thalassemia (Orkin et al., 1985). In
contrast, gain-of-function mutations due to CG to CA mutation within the prothrombin gene
creates an optimal cleavage site and increases the production of prothrombin mRNA by
enhancing cleavage and polyadenylation of the pre-mRNA. This event greatly increases the
predisposition toward thromboembolic disorders (Danckwardt et al., 2008; Gehring et al.,
2001).
In addition to these well-characterized human pathologies, several other lesserunderstood diseases are also associated with changes in the efficiency of 3′ end processing
of mRNA. Recently, it has been demonstrated that Facioscapulohumeral Dystrophy (FSHD)
can also be linked to single nucleotide polymorphisms that generate cis elements mediating
3′ end formation that affect the CPA of a pathogenic mRNA (Lemmers et al., 2010a).
Individuals with FSHD inappropriately express Dux4. The expression of Dux4 in
FSHD muscle cells is not only contingent on D4Z4 derepression, but also requires the
presence of a stable collection of single nucleotide polymorphisms (SNPs), or haplotype, in
a region of DNA downstream of the D4Z4 repeats. In the general population, there are two
equally common haplotypes of chromosome 4, namely A and B. Haplotype A, with which
FSHD is associated, is distinguished from haplotype B by the presence of a segment of
DNA called pLAM and a 6.2kb degenerate β-satellite repeat immediately downstream of the
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D4Z4 repeat (van Geel et al., 2002; Lemmers et al., 2004) (Figure 5.1). Concomitant with
the transcriptional depression at the FSHD locus, a SNP in the pLAM creates a functional
but non-canonical PAS (AUUAAA) that allows for the production of the Dux4 mRNA
(Lemmers et al., 2010a, 2012; Snider et al., 2010). Dux4, a homeodomain gene, is not
normally expressed in somatic cells but is robustly expressed in testes and is thus posited to
play a role in development (Dixit et al., 2007; Snider et al., 2010; Young et al., 2013). In
germline cells, Dux4 is alternatively spliced and uses a PAS distal to that which may be
created by SNPs in pLAM (Snider et al., 2010) .The inappropriate expression of Dux4 is
believed to contribute to muscle damage caused by various mechanisms including defects
in myogenesis via induction of apoptosis, immune response stimulation, and inappropriate
activation of germline transcription (van der Maarel et al., 2012).
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Figure 5.1. Schematic of Chromosome 4qA chromosome. Chromosome 4qA depicted with
hypermethylated transcriptionally silenced D4Z4 repeats (gray triangles) upstream of pLAM
and the β-satellite repeat region. Reduction in the number of repeats leads to
hypomethylation and transcriptional derepression. The image on the bottom magnifies the
terminal D4Z4 repeat and downstream sequences, and shows the Dux4 ORF in the D4Z4
repeats. The downstream sequences specific to the haplotype A, shows pLAM with a SNP
creating a PAS and the β-satellite repeats defined by recurring sites for the restriction
enzyme Sau3A.
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In patients with FSHD, the productive transcription of Dux4 mRNA is facilitated by
SNPs within certain haplotypes on chromosome 4 that supply a PAS. However, beyond the
non-canonical PAS, the cis sequence elements that define the context for 3′ end formation
of Dux4 are undefined. The purpose of this study was to identify cis sequence elements that
aid in the efficiency of cleavage and polyadenylation of Dux4 mRNA. We anticipated that the
Dux4 PAS would be weak because of its non-canonical nature and that it would require
additional regulatory elements to mediate 3′ end processing. Here, we use a transcriptional
read-through reporter (PAS-GFP) described previously in Chapter 4 to interrogate the cis
requirements of Dux4 cleavage and polyadenylation. With use of this tool, we identified a
previously uncharacterized element that is required to mediate Dux4 mRNA 3΄ end
formation. Surprisingly, this element, although potent in enhancing processing, is located
more than 100 nucleotides downstream of the PAS and is present within the β-satellite
region. This finding underscores the complexity of Dux4 expression and uncovers a
potentially new therapeutic target to inhibit Dux4 expression.
β-Satellite Sequences Contribute to Dux4 mRNA 3’ End Formation.
The pLAM sequence, which contains the SNP creating the PAS for Dux4, is ~240
base pairs and includes a portion of the terminal intron as well as the terminal exon 3
(Figure 5.1). To test the relative efficiency of this sequence to act as a CPA element, we
cloned pLAM into the PAS-GFP reporter (described in Chapter 4) and transfected this
construct into HeLa cells and HEK293T (Figure 5.2A). Surprisingly, despite a functioning,
albeit non-consensus, PAS present within pLAM, we observed a significant amount of GFP
expression relative to the SV40-GFP reporter. This could indicate that (1) the Dux4 PAS is
significantly weaker than SV40, (2) other sequence elements are required for efficient CPA,
(3) Neither HEK293T nor HeLa cells can recapitulate Dux4 CPA to the extent of muscle
tissues, or (4) the small portion of the terminal intron that was included in the pLAM-GFP
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reporter somehow disrupts recognition of the Dux4 PAS (Figure 5.2B/C, lane 2).To address
this last point, we also generated a PAS-GFP reporter containing only exon 3 upstream of
GFP. We observed that removal of the partial intron resulted in a slight decrease in GFP
expression; however, GFP protein was still readily detectable (Figure 5.2B/C, lane 3).
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Figure 5.2. Identifying the minimal region necessary to suppress GFP. (A). Schematic of the
terminal D4Z4 repeat pLAM and β-satellite to show the Dux4 constructs cloned upstream of
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the GFP ORF. (B and C). Western blots of cell lysates for HEK293T (left) and HeLa cells
(right). Loading control was α-tubulin, transfection control was αHA to recognize cotransfected HAmCherry.
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We then generated two more Dux4 reporters into which we inserted genomic
fragments containing increasing amounts of DNA flanking the pLAM PAS to include either
~100 nucleotides on either side of the PAS or ~200 nucleotides (Figure 5.2A). We observed
a total suppression of GFP expression only when ~200 nucleotides of sequence flanking on
either side of the pLAM PAS was included in the PAS-GFP reporter (Figure 5.2B/C, lanes 34). Finally, we conducted 3′ RACE on RNA isolated from the pLAM-GFP, Exon3-GFP, P100GFP or P200-GFP transfected cells. We observed that the primary product was due to
transcriptional read-through for the pLAM, Exon 3 and P100 sequence; however, when the
P200 sequence was used, we observed a small upstream cleavage product (Figure 5.3).
Sequencing of this smaller fragment confirmed that the Dux4 PAS is used, although the
cleavage site mapped to 1-2 nucleotides upstream of the annotated sequence.
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Figure 5.3. 3′ RACE of Dux4 constructs in PAS-GFP Reporter. On top, ethidium bromide
stained agarose gel with PCR products, amplified from HeLa cells transfected with Dux4
constructs, resolved to show upstream cleavage product and read-through product. On
bottom, sequence chromatogram of upstream cleavage product from clone P200, the PAS
and cleavage site are underlined.
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On the basis of the observation that additional sequences located on either side of
the Dux4 PAS are required for its efficient CPA, we sought to increase the resolution of our
analysis by using deletions. To first determine whether cis elements lie upstream or
downstream of the Dux4 PAS, we created two additional reporter constructs. The ΔD-GFP
reporter lacked 100 nucleotides from the 3′ terminus of P200, thereby removing the second
β-satellite repeat, whereas the ΔU-GFP reporter retained only 100 nucleotides upstream of
the PAS (Figure 5.4A). In agreement with results presented in Figure 5.2, we observed GFP
expression from the P100-GFP reporter but not from the P200-GFP reporter; moreover, we
noted GFP expression from the ΔD-GFP reporter but not from the ΔU-GFP reporter (Figure
5.4B/C). These results demonstrate that sequences that were removed in the ΔU-GFP
reporter are dispensable for Dux4 CPA, whereas sequences within the second β-satellite
repeat are required for Dux4 CPA. Altogether, these results indicate that sequences
downstream of the Dux4 PAS are required for its efficient use.
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Figure 5.4. Elements for Dux4 CPA lie downstream of PAS. (A). Schematic of Dux4 CPA
constructs cloned upstream of GFP. (B and C). Western blot of lysates from HEK293T and
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HeLa cells transfected with the constructs in (A). Loading control and transfection control
are α-tubulin and αHA respectively.
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Downstream Auxiliary Elements aids in cleavage and polyadenylation of Dux4.
To further delineate the location of the downstream element, we performed deletion
mutagenesis, in 20-nucleotide increments, of the terminal 100 nucleotides of the P200
sequence (henceforth called full-length, FL) (Figure 5.5A). By Western blot analysis, we
observed that we gained GFP expression when the last 40 nucleotides were removed from
the FL Dux4 CPA construct (Figure 5.5B). Following up with a fluorescence plate reader
assay to increase sensitivity, we observe that there is complete loss of GFP fluorescence
only in the FL construct, suggesting that an element lies within the last ~20 nucleotides. This
discrepancy may be as a result of the amount of protein loaded, and/or the sensitivity of the
GFP antibody used.
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Figure 5.5. Deletion series identifies element in the extreme 3′ terminus of the Dux4 CPA
construct. (A). Schematic of deletion constructs of Dux4 FL cloned upstream of GFP (B).
Western blot of lysates from HEK293T cells transfected with reporter containing Dux4 PAS
constructs shown in A. Loading control and transfection control are α-tubulin and αHA
respectively. (C). Quantification of data from plate reader assay of GFP fluorescence
normalized to co-transfected HA tagged mCherry. Hatched vertical line indicates where the
sensitivity of the Western blot is diminished. Error bars calculated from standard deviation of
biological triplicates.
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To achieve even greater resolution of the regulatory element, we compared the
constructs Δ40 and Δ60, and further made transversion mutations in six-nucleotide clusters
within the region that the Δ40 possess and the Δ60 lacks (Figure 5.6, left). We observed that
there is an increase GFP expression, when mutations of the last six nucleotides are made,
which reproduced using a fluorescence plate reader (data not shown).
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Figure 5.6. Point mutation analysis in construct Δ40 compared with Δ60. (Left) Schematic of
the Dux4PAS constructs showing Δ40 and Δ60, transversion mutations of six nucleotides
were made in the 3′terminus of the Δ40 construct. Wild type sequence depicted in lower
case, mutations are shown in upper case. (Right) Western blot of Dux4PAS constructs
depicted on left. Loading control and transfection control are α-tubulin and αHA respectively.
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We further assessed the validity of our data, by making transversion mutations in the
context of our full-length Dux4 CPA (Figure 5.7, left). Due to the weak signal we quantified
the expression of the GFP from three different experiments, and our analysis of the western
blots (Figure 5.7, right) re-identifies the cis regulatory element (mutant C) identified in the
context of the Δ40 mutants in (Figure 5.6). In addition, we identify near the 3′ end of the full
length Dux4 CPA another element (mutant K), wherein mutation of this sequence resulted in
increased GFP expression. In the second instance we mutated AGAGA to CTCTC, while the
first element identified in both point mutation analyses share an overlap of the nucleotide
AAC mutated to CCA. Mutated sequences that increase GFP expression were over 150 130 nucleotides downstream of the Dux4 polyadenylation signal and cleavage site,
respectively. Here we identify downstream sequences that are required to suppress GFP
expression which we correlate with facilitating cleavage and polyadenylation at the Dux4
PAS. Nonetheless, we acknowledge that confirmation of their importance for 3′ end
processing requires the analysis of the RNA levels. A limitation of the PAS-GFP reporter is a
consequence of the immunoblotting or fluorescent readout for the analysis of CPA events.
To ensure that the reporter protein is produced, it is imperative that the upstream PAS: (1) is
cloned in frame, (2) contains no in frame stop codons or start codons if the native reporter
start codon is used, and (3) contains no start codons out of frame with the reporter protein
ORF. All these consideration as well as those discussed in Chapter 3, limit the scope of the
PAS-GFP reporter while site-directed mutagenesis to remove these elements may interrupt
or create alternative cis regulatory elements.
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Figure 5.7. Effects of mutation in Dux4 Downstream Auxiliary Element (DAE). (Left) Schematic of the Dux4PAS constructs
depicting transversion mutations of five nucleotides made in the DAE of Dux4. (Right) Representative western blot of Dux4PAS
constructs depicted on left. Quantification of western blots from 3 experiments performed using Biorad Image Lab software, and
mutants with reproducible increases in GFP expression shown. Loading control and transfection control are α-tubulin and αHA
respectively.
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Evaluating Dux4 3′ end processing “natively”
To further assay Dux4 processing we placed the Dux4 P200 construct downstream
of the mCherry ORF. Surprisingly, we did not detect robust mCherry expression, although
we observed a 3′ RACE product from the P200 construct (not shown).To determine if the
UTR is destabilizing we used the dual luciferase reporter system and placed the terminal
exon of pathogenic Dux4, Exon 3, into the psiCheck 2 vector (Figure 5.8). However, we did
not see any decrease in luciferase expression. Consequently, we switched models, and
moved the 3’ UTR into a splicing capable reporter (Figure 5.9A). As a consequence of
frequent PCR errors and recombination events due to the repetitive nature of the Dux4
sequence, we opted to further modify the region cloned downstream of the GFP ORF such
that we retained 100 nucleotides upstream of the Dux4 polyadenylation signal and 500
nucleotides downstream of the of the PAS, as we previously showed that elements
downstream of the PAS were critical for 3′ end processing (Figure 5.2). When the Dux4 CPA
elements were placed downstream of an intron containing GFP, we observed robust protein
expression, similar to SV40. Moreover, the strength of the GFP expression was directly
related to presence of downstream auxiliary elements of Dux4 (Figure 5.9B). 3′RACE of the
reporter containing solely the Dux4CPA produced a polyadenylated product cleaved as
reported in the literature and as observed with our PAS-GFP reporter. However, we also
observed that there was another band present which when sequenced showed a cleavage
product due to utilization of a PAS (not identified) in the vicinity of the GFP stop codon. This
product would correspond to GFP transcript with a short UTR (Figure 5.9C). Due to the lack
of any destabilizing elements in the Dux4 UTR cloned as determined by luciferase assay,
we speculate that the upstream splicing aided in cleavage and polyadenylation with the
Dux4 PAS. Alternately, the usage of an alternate polyadenylation signal in the reporter
containing the full Dux4 CPA, may result in a robust protein production not dependent on an
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mRNA cleaved and polyadenylated at the Dux4 CPA element. However, this is unlikely, as
we observe that substituting the 100 nucleotides upstream of the Dux4 polyadenylation
signal with the minimal SV40PAS upstream sequence elements, also produced robust GFP
expression and we detect only a single band in the 3′ RACE (Figure 5.9C). Moreover,
sequencing of the PCR product showed that the cleavage and polyadenylation event
occurred at the same location as used by the full intact Dux4PAS. In contrast, creating a
reciprocal construct, in which the downstream sequence elements (DSE) of SV40PAS are
placed after the Dux4 polyadenylation signal, we observed that the primary cleavage and
polyadenylation event occurs downstream of the SV40 DSE, suggesting the use of another
unidentified polyadenylation signal (Figure 5.9).
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Figure 5.8. Histogram of terminal Exon 3 of pathogenic Dux4 in dual luciferase reporter.
Exon 3 cloned downstream of Renilla luciferase and transfected into HEK293T cells. Renilla
luciferase expression was normalized to Firefly luciferase. Error bars shown depict standard
deviation of biological triplicates.
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Figure 5.9. Reporter gene expression as a result of Dux4PAS. (A). Schematic of reporter
showing intron-containing GFP, cloned downstream are the SV40PAS, Dux4PAS and
chimeric constructs which retain the Dux4 hexanucleotide polyadenylation signal, but have
either sequence upstream or downstream of the polyadenylation signal substituted for the
complementary elements in the SV40PAS. Blue boxes represent SV40 sequences and
green boxes represent Dux4 sequences. In pictogram of SV40 gray rectangle denotes
polyadenylation signal and red line indicates cleavage site. In the pictogram of the Dux4
construct, black rectangle indicates the polyadenylation signal, and red line shows the
cleavage site used. The chimeric construct DUSD contains 100 nucleotides of Dux4 UTR
sequences upstream (green box) of the Dux4 PAS (black rectangle), and extends to the
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cleavage site (dotted line).The 96 nucleotide SV40DSE is immediately downstream of the
cleavage site. Red line denotes the cleavage site used. The chimeric construct SUDD
contains 100 nucleotides of SV40 upstream sequence elements (blue bar), the Dux4PAS
(black rectangle) and the Dux4 DAE (green bar). The cleavage site used is indicated by the
red line. (B). Representative western blot HEK293T cells transfected with constructs shown
in A. Transfection control depicts co-transfected myc tagged mCherry. Loading control and
transfection control are α-GAPDH and α-myc respectively. (C). Ethidium bromide stained
2% agarose gel showing 3′ RACE products obtained from the HEK293T cells transfected
with constructs depicted in A. RT denotes reverse transcriptase, and + or -, represents the
presence or absence of reverse transcriptase in the cDNA synthesis. Untransfected
HEK293T cells were also included in the 3′RACE.
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Design and Use of ASO targeting CPA
The utility of RNA as both a target and a modality to influence gene expression is
rapidly becoming mainstream. This has been spurred by recent advances in nucleic acid
based technology such as clustered regularly-interspaced short palindromic repeats
(CRISPR), and improvement in commercially availability of chemically modified nucleic acids
(Haussecker, 2016). One of the broadest methods to target RNA and modify gene
expression uses antisense mechanisms (reviewed (Kole et al., 2012; Potaczek et al.,
2016)). This is exemplified by the increasingly common place use of RNA interference
(RNAi) and antisense oligonucleotides (ASOs). The simplest definition of an ASO would
describe a short polymer of the nucleotides A, T, U, C or G as a ribose or deoxyribose
sugar, which is used to bind RNA or DNA molecules through base pairing. ASOs are
typically modified to increase affinity, stability and accessibility. Increases in the stability, that
is resistance to nucleases, can be accomplished by modifying the backbone chemistry; for
example, using phosphorothioate bonds in lieu of a phosphodiester bonds for polymer
conjugation. However, while a phosphorothioate backbone increases ASO stability, it also
reduces the affinity of the ASO for the target and introduces chirality (Koziolkiewicz et al.,
1995), and indeed alternative backbones have been investigated to achieve increased
nuclease resistance without loss of affinity (Freier and Altmann, 1997). Additional
modifications, when an RNA template ASO is in use, include substituting the reactive 2′
hydroxyl group with a more stabilizing or neutral group. With such substitutions, the loss of
binding affinity caused by using a phosphorothioate backbone can be rescued (and further
improved). Likewise, in the context of a phosphodiester backbone, substitution of the 2′
hydroxyl group can increase nuclease resistance of ASOs (Monia et al., 1993, 1996) .
Common substitutions are 2′-O-methyl or 2′-O-fluoro. Alternatively, nucleoside analogues
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such as peptide nucleic acids (PNA), locked nucleic acids (LNAs), phosphorodiamidate
morpholino oligomers (PMOs) may be used.
Antisense strategies, can be exploited in many ways for example, RNAi is a routinely
used antisense strategy and employs small RNAs (short interfering RNAs, microRNAs)
incorporated in the RNA induced silencing complex (RISC) machinery to decrease
translation of target mRNA and degrade the RNA (reviewed by (Iwakawa and Tomari, 2015;
Jonas and Izaurralde, 2015)). In the case of ASOs, the chemistry and design affects the
behavior when it interacts with the target substrate. One such application ASOs is to
degrade the RNA and downregulate gene expression. This method takes advantage of the
nuclease, RNase H, which cleaves RNA molecules in RNA:DNA hybrids (reviewed (Bennett
and Swayze, 2010; Crooke, 2004)). However, not all ASOs are meant to degrade RNA.
Fully modified antisense oligonucleotides which do not induce RNase H action ASOs can be
and have been used to repurpose the molecule by affecting how it is processed (reviewed
(Bennett and Swayze, 2010; Kole et al., 2012)). The best studied application in modulating
RNA processing, is the use of ASOs to change splicing events. In this instance, the ASOs
are designed to bind RNA and sterically impair protein:RNA interactions, such as those
between splicing factors and exonic splicing silencer or enhancers, thus promoting exon
inclusion or skipping. The application of ASOs in redirecting splicing has been widely
explored, however, there are other RNA processing events which can be interrogated by
splicing (Kole et al., 2012; Sazani and Kole, 2003).
Cleavage and polyadenylation of mRNA is a tenable target for application of ASOs,
and others have shown that using CPA targeting ASO can redirect polyadenylation signal
choice or impair CPA altogether (Marsollier et al., 2016; Vickers et al., 2001). Moreover, they
have been used to elucidate molecular mechanisms behind RNAPII termination events
(Zhang et al., 2015). Here, we design steric blocking ASOs targeting CPA elements of
endogenous genes and reproduce a redirection of polyadenylation signal choice. In addition,
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we use steric blocking and RNase H sensitive (gapmer) ASOs to interrogate the elements
critical for 3′ end formation of Dux4 mRNA in a reporter system, and to downregulate the
endogenous expression of the gene.

Short Antisense Oligonucleotide shows primarily nuclear localization
We designed a short, 15 nucleotide ASO, with a fluorescein moiety at the 5′ end,
ASO-2F (Table 3.5) and transfected this nucleotide into RD cells, HEK293T, HeLa, and an
immortalized FSHD patient myoblast cell line, 15Abic CT#24. HEK293T cells were
transfected with ASO 2F at concentration ranging from 100nM to 2.5µM, and cells were
visualized by microscopy twenty four hours after transfections. The immortalized patient
myoblast cell line was transfected at the same concentrations of ASO. Twenty four hours
after transfection the cells were shifted to differentiation medium, and cells were ultimately
visualized by microscopy five days after inducing differentiation (see Chapter 3, methods).
While there was minimal toxicity to HEK293T cells to even the highest dose of ASO
used, we did observe that the 15Abic cells were less resilient. The toxicity of the higher
doses (>500nM) of ASO-2F to 15Abic cells is likely to account for the decreased myotube
formation observed (Figure 5.10). Furthermore, we observed that in addition to the toxicity,
the localization of ASO-2F in 15Abic cells was primarily cytoplasmic at lower concentrations,
however, the ASO was enriched in the nucleus with increasing concentrations. In contrast,
ASO-2F was primarily nuclear (Figure 5.11) at low concentrations in HeLa, HEK293T and
RD cells. However, as the ASO concentration increased, the localization became more
diffuse and punctate (Figure 5.12). Differences in ASO behavior dependent on the cell line
has been previously reported (Crooke, 2004). Another consideration, that after six days the
fluorescein group on the ASO may have been hydrolyzed and the observed fluorescent
signals were the consequence of free fluorescein. However, we do observe that there
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appears to be diffuse localization of the ASOs in the cells even after changing the medium
at 4 hrs post transfection.
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Figure 5.10. Fluorescein labelled Antisense Oligonucleotide transfected into immortalized
FSHD patient cells. Images of 20X magnification of 15Abic CT#24 cells, five days after
initiating differentiation, six days after transfection with fluorescent ASO. Phase contrast
images (BF), DAPI and green fluorescence images shown, for cells transfected with
increasing concentrations of fluorescent ASO. Toxicity observable at higher concentrations
(1µM) where there is an increase in the balled cells as well as decreased cell density.
Transfection of lower concentrations (0.1 and 0.500µM) had less toxicity and cell
morphologies were consistent with healthy growing cells upon verge of differentiation,
although we do not observe robust myotube formation (multinucleated cells). Increasing
concentration of ASO resulted in more diffuse localization of ASO, as well as the
appearance of punctate spots. Exposure times were kept constant.
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Figure 5.11. Merged Images of cells transfected with low concentration of Fluorescein
labelled ASO. (Top) Merged bright field (BF) and green channel images (GFP) of HeLa,
HEK293T and RD cells transfected with 100nM fluorescein labelled ASO at 10X
magnification. Localization of the ASO is primarily nuclear. (Bottom) Merged images (bright
field with DAPI and bright field with GFP) of immortalized FSHD patient cells transfected
with 100nM fluorescein labelled ASO at 10X magnification. Localization heterogeneous,
majority of cells show cytoplasmic localization, but some cells show both nuclear and
cytoplasmic localization.

141

Figure 5.12. Microscope images at HEK293T cells transfected with increasing
concentrations of fluorescein labelled ASO. Bright field (BF) images show little cellular
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toxicity, in the green channel (fluorescein) increasing concentration of ASO in more visibly
fluorescent cells and more diffuse localization of ASO in the cell. Exposure times were kept
constant.
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Determining the utility of ASOs with use a reporter
As a proof of principle and to investigate the utility of CPA targeting ASOs to
decrease protein expression we designed ASOs targeting the SV40 polyadenylation signal.
We generated a reporter in which the SV40PAS is placed downstream of an intron
containing GFP ORF. The HEK293T cells were first transfected with antisense
oligonucleotides, and later transfected with reporter (see Chapter 3 Methods). After 48 hrs,
the cells were harvested for protein. Western blot analysis and quantification demonstrates
that the different approaches have different levels of efficiency, and also that the chemistry
employed has different levels of antagonistic effects for protein expression. Using this
protocol we observed that both steric and gapmer ASOs resulted in ~70% decrease in
protein expression, however, the decrease was modest and not significant with the steric
blocking ASO (Figure 5.13).
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Figure 5.13. Western blot of HEK293T cells transfected using with SV40 PAS directed
ASOs using a two hit protocol. Cells were first treated with ASOs, subsequently cells were
simultaneously transfected with ASOs plasmid containing SV40PAS downstream GFP.
Control ASO is a scrambled version of the SV40PAS directed ASO. Loading control and
transfection control are α-GAPDH and α-Cherry respectively. Quantification performed using
Bio-Rad Image Lab on western blots from biological triplicates. Error depicts standard
deviation of biological triplicates. (A). Western blot of HEK293T cells transfected using 2hit
protocol with 100nM SV40PAS directed gapmer ASO. (B). Western blot of HEK293T cells
transfected using 2hit protocol with 100nM SV40PAS directed steric ASO.
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Two limitations of the two-hit protocol used above are pretreatment of the ASOs, as
well as co-transfection with the reporter. It is conceivable in the latter instance, that cotransfecting the ASO with the reporter may be biased toward either the plasmid DNA or the
ASO. Another possibility is that there is segregation of plasmid and ASO upon transfection
such that cells which are transfected with ASOs do not necessarily take up the plasmid
DNA, and vice versa. The first caveat in which the cells are pre-treated with ASO prior to the
addition of the reporter, may influence the data in that cells do not have a pre-existing pool
of the target substrate, so the data would have a limited range of applicability. Similar
protocols have been employed by others in which cells are induced to produce the gene of
interest subsequent to addition of the antisense (Bennett et al., 1992; Chiang et al., 1991;
Vickers et al., 2001). To address these limitations, we first transfected the reporter, and
following transfection of the reporter we treated the cells once or twice with antisense
oligonucleotides (see Chapter 3 Methods). To deplete the preexisting pool as well as
decrease subsequent production we transfected a higher concentration of both steric and
gapmer ASO. Once more we observe a ~70% reduction in GFP protein expression with a
PAS directed gapmer ASO (Figure 5.14). Although, we do see a reduction in the GFP
protein expression with PAS directed steric ASO, there was high degree of variability which
resulted in a loss of significance. A pertinent consideration in this approach would be the
consideration of the half-life of the reporter protein (estimated to be 26 hrs) (Corish and
Tyler-Smith, 1999)and mRNA, however, cells are harvested for protein 48 hrs post
transfection which should provide sufficient time to observe an effect.
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Figure 5.14. Western blot of HEK293T cells transfected using with SV40 PAS directed
ASOs. Cells transiently transfected with plasmid containing SV40PAS downstream GFP,
and subsequently transfected with 1.25µM of ASO. Control ASO is a scrambled version of
the SV40PAS directed ASO. Loading control and transfection control are α-GAPDH and αmyc respectively. Quantification performed using Biorad Image Lab on western blots from
biological triplicates. Error depicts standard deviation of biological triplicates. (A). Western
blot of HEK293T cells transfected with1.25µM SV40PAS directed gapmer ASO. (B).
Western blot of HEK293T cells transfected using 2hit protocol with 1.25µM SV40PAS
directed steric ASO.
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Having cloned the Dux4PAS and DAE downstream of the intron-containing GFP, we
attempted to use CPA targeting ASOs to decrease the reporter protein expression. In our
pilot experiments we first transfected HEK293T cells with the reporter containing the
Dux4PAS, and subsequently transfected the cells with increasing concentrations of ASO,
targeting the PAS and DAE. Using gapmer ASOs, we were not able to achieve reproducible
depletion in GFP expression when cells were transfected with the PAS directed ASO
compared to the control treated cells (not shown). Likewise, changes in the GFP expression
in cells transfected with steric ASO, were highly variable. One cause for concern is the
usage of alternate PAS in the reporter when Dux4 CPA elements are placed downstream
(Figure 5.9) this could prevent the detection of any changes in the protein expression, due to
inducing alternative cleavage polyadenylation. As such, we feel that further optimization is
necessary. One method to address this concern, would be the development of a stable
clonal line with a reporter using the Dux4PAS. However, care would have to be taken to
ensure that GFP expression detected is as a consequence of Dux4PAS usage, and not due
random integration into the genome supplying alternative polyadenylation signals. Using an
analogous reporter in which we have the chimeric SV40UTR/Dux4PASDAE (Figure 5.9)
placed downstream of the intron-containing GFP we generated clonal stable cell lines.
Although amplification of genomic DNA suggested that all the elements Dux4CPA
downstream of the intron containing GFP were present as desired (Figure 5.15) we
observed the difficulty in identifying clones that solely use the Dux4 CPA (Figure 5.15).
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Figure 5.15. Ethidium Bromide stained agarose gels of stable GFP positive clonal lines.
(Top) 2% agarose gel with products of nested PCR amplification of genomic DNA to identify
GFP positive clones that had the GFP ORF and Dux4PAS and CPA elements downstream.
PCR products were excised and purified, then submitted for sequencing and restriction
digest screen. The * (positive control) indicates the parental plasmid used to generate the
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stable cell line amplified by PCR. (Middle) Clones which were positive in the nested PCR
amplification, were digested with BamHI and EcoRI and resolved on 3% agarose gel. The *
indicates the control positive control PCR product digested also with BamHI and EcoRI.
(Bottom) 3′ RACE on clonal lines which contained GFP upstream of the Dux4PAS.
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Redirecting CPA
We next turned our attention to an endogenous gene in HeLa cells. Dicer has
multiple polyadenylation signals (Masamha et al., 2014). We designed both steric and
gapmer ASOs targeting the distal PAS of Dicer. A double transfection of 100nM dicer siRNA
using the standard two hit protocol (see Chapter 3 Methods) was able to give robust
knockdown ~80% compared to a non-targeting siRNA (Figure 5.16). Comparatively, we
performed a single transfection of both steric and gapmer ASOs targeting Dicer1 at a final
concentration of 100nM, and observe that a PAS directed gapmer ASO produced a ~4050% decrease in the Dicer1 mRNA levels, when measured using a primer within the ORF
and a primer which detects Dicer1 transcripts using a distal polyadenylation signal. In
contrast, using the PAS directed steric blocking ASO, we did not detect a significant
decrease in the overall Dicer1 mRNA levels, and instead, we observed ~ 60% decrease in
usage of distal polyadenylation signal. We interpret the data presented here, as redirection
of the polyadenylation signal choice by a PAS directed steric ASO. The availability of more
than one polyadenylation signal likely, limits the extent of knockdown that can be achieved
with the steric blocker. In contrast, the gapmer ASO allows for degradation of the mRNA due
to the action of RNase H, regardless of whether or not there is an alternative
polyadenylation signal. In addition, the gapmer ASO is not restricted to working during the
process of CPA, but can also lead to degradation of the processed mRNA in both the
cytoplasm and nucleus. Increasing the concentration of gapmer ASO or following a two hit
protocol similar to the siRNA transfection may increase the level of knockdown. Although the
depletion would be most observable in transcripts using the distal polyadenylation signal.
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Figure 5.16. PAS directed ASO redirect PAS or reduce gene expression. (Top) Schematic of
Dicer1 open reading frame (ORF) and untranslated region (UTR), head to head arrows
indicate the location of the primers used to amplify Dicer. Vertical bars in the UTR denote
position of the proximal (pPAS) and distal (dPAS) polyadenylation signal. Horizontal lines
with diagonal hatches indicate location of siRNA and PAS-Directed ASO. (Bottom) qRTPCR analysis of HeLa cells transfected with control or Dicer1 siRNA (siD1#1), and both

152

steric and gapmer ASOs directed toward the distal polyadenylation signal of Dicer1.Control
ASOs are derived from a scramble of the SV40PAS directed ASO. Error bars calculated
from standard deviation of biological triplicates. Distal and proximal polyadenylation signal
indicated are as previously described by Masamha et al. 2014. Primers to amplify Dicer1
common and distal previously described by Masamha et al. 2014.
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Dux4 in 15Abic cells
One of our primary goals was to decrease the Dux4 protein expression. Dux4 is
typically poorly expressed, and detection is difficult. Nonetheless, we attempted to detect
Dux4 protein in the 15Abic immortalized cell line. We immunoprecipitated with a Dux4
antibody (9A12) that recognizes the Dux4 (but is reported to cross hybridize with other
Dux4-like proteins) and then subsequently performed a western blot to detect Dux4 using an
antibody which uniquely recognizes the Dux4 C-terminus (Geng et al., 2011). Consistent
with previous reports that Dux4 is induced upon differentiation (Block et al., 2013), we
observe a strong signal at ~55kDa (likely Dux4) (Figure 5.17A), due to the predicted size of
the Dux4 protein being 45-52kDa. However, contrary to previous reports (Pandey et al.,
2015), substitution of knockout serum replacer (KOSR) in place of horse serum (HS) in the
differentiation medium, did not enrich or stimulate for Dux4 protein detection (Figure 5.17B).
Knockout serum replacer is posited to enhance myotube formation, which would
consequently promote Dux4 expression (Block et al., 2013). However, it is notable that, at
the time of lysis, both the horse serum and knockout serum replacer differentiated cells had
roughly the same amount of multinucleated cells (not shown).
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Figure 5.17. Detecting Dux4 Protein in Immortalized FSHD patient lines. (A). Western blot
probed with α-Dux4 (E5-5) of 5Abic myoblasts (MB) and myotubes (MT) immunoprecipitated
with α-Dux4(9A12). Protein marker shown. (B). Western blot of 15Abic myoblasts (MB) and
myotubes (MT). Myoblasts were differentiated over 5 days in either 20% Knockout Serum
Replacer (KOSR) or 2% Horse Serum. Blots probed for differentiation marker myosin heavy
chain (α-MHC) and Dux4 protein with αDux4 (E5-5). Loading control is α-GAPDH.
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Conclusions
Here, I identified that additional cis regulatory elements, besides the non-consensus
PAS are required for cleavage and polyadenylation of Dux4. Previous bioinformatics
analyses posit that RNA elements critical for cleavage and polyadenylation optimally lie
within 100 nucleotides of cleavage site and are typically Uridine rich (Hu et al. 2005;
Legendre and Gautheret 2003). The location of these cis regulatory elements for Dux4
cleavage and polyadenylation are outside the optimal 100 nucleotide window downstream of
both the polyadenylation signal and the cleavage site. Moreover, this element lies within a
degenerate repeat regions, which leads us to form two hypotheses to model Dux4 cleavage
and polyadenylation. The cis elements identified are not enriched for uridines, and the
degeneracy of the repeats impairs the identification of similar motifs, although the
commonality between the regions identified to increase GFP expression seems to be biased
toward purines.
In the context of our reporter, we identify a DAE that appears to enhance Dux4
mRNA 3′ end processing from the non-consensus PAS. Thus, we present the following
models for how the DAE identified enhances CPA of Dux4 (Figure 5.18). We propose that
the DAE facilitates efficient cleavage and polyadenylation by one of two potential
mechanisms. The first involves the recognition of the DAE within the nascent pre-mRNA by
a yet-to-be identified RNA binding factor that would enhance the recognition of the PAS by
the CPSF machinery.
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Figure 5.18. Model of Dux4 Processing. (A.) RNA binding proteins interacting with the
downstream auxiliary element (DAE) identified may facilitate Dux4 cleavage and
polyadenylation by aiding in the recruitment of CPSF machinery to the non-consensus PAS.
Alternatively, (B). The DAE may be a DNA element that induces RNA pauses due either to
sequence identity of protein blockage. The stalled polymerase kinetically favors cleavage
and polyadenylation at the non-consensus Dux4 PAS.
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An alternative explanation, is that the DAE aids in the 3’ end formation of Dux4
mRNA by pausing (or terminating) of the RNA polymerase. Polymerase pausing is well
defined in terms of its role in transcription initiation, particularly for stress response genes
(Kwak and Lis 2013), however, less is known about the role of RNAPII pausing to facilitate
mRNA maturation. One of the best understood pausing elements, which can influence
mRNA 3’end processing, is the MAZ sequence (Yonaha and Proudfoot 1999, 2000). It has
been shown that placement of MAZ elements downstream of the of poorly defined exons
such as α-tropomyosin exon 3 or Fibroblast Growth Factor Receptor II exon IIIb, increases
their inclusion presumably through providing additional time for splice site recognition
(Roberts et al. 1998; Robson-Dixon and Garcia-Blanco 2004).
Upon cloning the Dux4 CPA downstream of mCherry we disappointingly did not
observe robust expression. However, as we found increasing the β-satellite repeats
sequences downstream increased reporter expression. Significantly, we also observed that
introduction of splicing upstream of the Dux4CPA increased our detection of the Dux4
mRNA. However, due to the presence of additional cleavage products in the 3′RACE we
cannot exclude that the Dux4CPA elements may result in a lower production of mRNA
compared to the upstream PAS.
Finally, using the knowledge acquired we designed Dux4 CPA targeting ASOs to
prevent protein expression. We undertook proof of principle experiments and demonstrate
that CPA targeting ASOs can decrease gene expression or redirect cleavage and
polyadenylation. Unfortunately, we have not yet been able to directly impair gene expression
using Dux4PAS targeting ASOs in either our reporter system or in patient cell lines. In the
immortalized patient cell line we observed a wide range of toxicity in response to several of
the ASOs tested in 15Abic cells. In our reporter system, we do not get reproducible
decrease in reporter protein expression. Analysis of the RNA would illuminate whether we
are observing alternative polyadenylation in the reporter system. Further, in the patient cell
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lines optimization of the ASO delivery, with due consideration for the ASO chemistry that we
have accessible, is required.
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Chapter 6 : Conclusions, Perspectives and Future Directions
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Downstream Auxiliary Sequences aid cleavage and polyadenylation of Dux4PAS
Using a transcriptional read-through reporter, we confirm that additional cis elements
are required for cleavage and polyadenylation (CPA) of Dux4 besides the non-consensus
polyadenylation signal (PAS). Moreover, this element is not located within a 100 nucleotides
of either the Dux4 PAS, or the cleavage site. Interestingly, the downstream auxiliary
element lies within a degenerate repeat region, called β-satellite DNA. Moreover using the
RegRNA2.0 tool (http://regrna2.mbc.nctu.edu.tw/index.html) (Chang et al., 2013), we do not
observe an enrichment for any known RNA motifs associated with cleavage and
polyadenylation within this region.

Testing a Model: Are the Dux4PAS auxiliary sequences RNA or DNA?
In Chapter 6, we propose two models describing how the downstream auxiliary
sequence elements (DAE) may aid in CPA of Dux4. While the models are not necessarily
mutually exclusive, we can interrogate the downstream sequences to examine the extent to
which either DNA or RNA elements facilitates CPA of the Dux4PAS. To interrogate the
model that the DAE is a DNA element we may use two complementary methods: Nuclear
Run-On assay and transcriptional pausing assay. Previously, we attempted to use a nonradioactive Nuclear Run-On assay to interrogate Dux4 PAS sequence elements for
transcriptional pausing in PAS-GFP reporter transfected cells, however, our available cell
lines proved refractory to labelling with 5-Bromouridine. The Nuclear Run On/Off Assay (Li
and Chaikof, 2002; Smale, 2009), provides a cell based method to assay nascent and active
transcription on genes. However, we can use also use the assay to comparatively
demonstrate the absence of transcription in the regions that are anticipated to not have
robust transcriptional activity due to termination events (Skourti-Stathaki et al., 2011), such
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as cleavage and polyadenylation of the mRNA and the subsequent removal of the RNA
Polymerase II (RNAPII) from the template. However, this assay does not prove pausing, and
as such the complementary cell-free transcriptional pausing assay, such as the G-Less
Cassette Assay (Carey et al., 2010) is also useful to investigate this hypothesis of
transcriptional pausing.
To address the hypothesis that the DAE functions primarily as an RNA element,
antisense oligonucleotides (ASO) may serve as a useful tool. The utility of ASOs for
therapeutic intervention is slowly growing (Kole et al., 2012; Potaczek et al., 2016), however,
we can also use ASOs in cell-free RNase protection assays and cleavage and
polyadenylation assays to interrogate the relevance of the RNA DAE for processing. Steric
impairment of DAE:Protein interaction (Zhang et al., 2015) or removal of the DAE by RNase
H activating ASO may reveal whether the DAE in the pre-mRNA is critical for cleavage and
polyadenylation.

The significance of non-canonical cis elements for cleavage and polyadenylation and
their interactions with cleavage and polyadenylation trans factors
The size and complexity of protein factors required to cleave the mRNA transcript
from transcribing RNAPII and DNA template underscores the importance of cis regulatory
elements to facilitate accurate and correct cleavage and subsequence polyadenylation ((Shi
et al., 2009)and reviewed in part (Chan et al., 2011; Wahle and Rüegsegger, 1999; Yang
and Doublié, 2011)). It has been shown that WDR33 and CPSF30, as part of the cleavage
and polyadenylation specificity factor (CPSF) recognize and bind to the consensus PAS,
AAUAAA (Chan et al., 2014; Schönemann et al., 2014). WDR33 appears to preferentially
associate with Uridines immediately downstream of the PAS, while the CPSF30 shows a
preference toward the AU PAS (Schönemann et al., 2014; Shimberg et al., 2016). However,
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in the case of non-consensus PAS, the tolerance for the divergence from the AAUAAA and
low Uridine enrichment is unclear (Chan et al., 2014; Schönemann et al., 2014; Shimberg et
al., 2016). Interestingly, although AUUAAA is fairly frequently used as a PAS, (~17%
compared to >50% for the AAUAAA, and <20% for other variants) (Tian and Graber, 2012),
WDR33 enrichment at AUUAAA PAS was low compared to the AAUAAA and other variants
(Schönemann et al., 2014). In the case of pathogenic expression of Dux4, the PAS used is
AUUAAA; and although there is a short stretch of containing two small Uridine tracks (<4
nucleotides) and intermittent presence of UG, immediately downstream of the cleavage site,
there is no apparent enrichment elsewhere. Additionally, using our PAS-GFP reporter, we
demonstrate that a cleavage product with Dux4PAS is detected when we place more than
100 nucleotides downstream of the PAS, the additional sequences do not show an
enrichment for Uridine stretches.
Cleavage and polyadenylation assays suggests that cleavage after a non-adenosine
nucleotides is poor (Sheets et al., 1990). In the literature the reported cleavage site of Dux4
is AG (Lemmers et al., 2010a; Snider et al., 2009). The RNA template within this region
reads AGA and so could be cleaved at either the G or A. In our hands, we reproducibly
detect a cleavage product within the TATA region a single nucleotide upstream of the GA.
However, an important observation here is that the cleavage site is close to the upper limit
downstream of the PAS; cleavage and polyadenylation typically occurs within 30 nucleotides
of the PAS (Chan et al., 2011). While there is a known micro-heterogeneity in cleavage site,
the significance is unclear (Chan et al., 2011). However, we believe that an additional
consideration should be whether there is a relevance between PAS consensus (that is the
sequence of the PAS as well as the presence and strength of USE and DSE) and the
distance of cleavage site from the PAS. Mutation of the cleavage site does not significantly
impair processing, because the endonuclease, CPSF73, can simply cleave the RNA at an
alternate location, these observations were reported in the context of a RNA substrates
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modelled on the late SV40 polyadenylation signal or L3 adenovirus-2 polyadenylation signal
that bare the consensus, PAS, AAUAAA (this study and (Mandel et al., 2006; Sheets et al.,
1990)).
We propose that the Dux4 PAS, with its paucity of notable motifs for CPA, would be
a good substrate to interrogate the factors that bind to a non-consensus PAS. By developing
a stable cell line with the gain of function reporter (such as the PAS-GFP) using the
Dux4PAS, a large scale CRISPR/Cas9 screen (Shalem et al., 2014) can be then employed
to identify genes which cause of loss of cleavage and polyadenylation of Dux4. Identified
genes can then be investigated using RNA immunoprecipitation or RNA binding assays to
determine interaction with Dux4PAS. Likely such a screen would provide a lot of candidates;
thus to narrow the investigation, combining unbiased RNA immunoprecipitation and mass
spectrometry to identify proteins interacting with the Dux4PAS with the aforementioned
CRISPR/Cas9 screen to identify genes that result in loss of cleavage and polyadenylation of
Dux4 would be ideal.
Chromosome 10 contains D4Z4 repeats, and pLAM and is nearly identical to the
D4Z4 repeats and pLAM on chromosome 4, however FSHD is exclusively associated with
the hypomethylation of D4Z4 repeats on chromosome 4 (van Geel et al., 2002; Lemmers et
al., 2010b; van Overveld et al., 2003; Wijmenga et al., 1992).Non-pathogenic single
nucleotide polymorphisms (SNPs) generate ATTTAA or ATCAAA, which are not recognized
as PAS on chromosome 10. Interestingly, placing the pathogenic SNP (generating ATTAAA)
in the context of a non-permissive chromosome 10 supported cleavage and polyadenylation,
albeit inefficiently (Lemmers et al., 2010a). Nonetheless, we posit that the context of the
SNP that generates the PAS is critical for CPA of Dux4. It is imperative to consider what
additional SNPs are present that allow for the AUUAAA to be used as a PAS for Dux4, and
also to what extent does the degeneracy of the β-satellite repeats affect the CPA? While
overwhelming evidence supports the hypothesis that poor expression of Dux4 expression is
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a consequence of dysregulated epigenetic silencing (resulting in a leaky and stochastic
event), it is also possible that cleavage and polyadenylation at this non-consensus PAS is
impaired due to the degeneracy of the downstream β-satellite repeats. There have been
dissenting data presented that discounted the importance of the pathogenic SNP, there exist
individuals who fit the molecular criteria for FSHD, but who do not present with disease
(Ricci et al., 2013; Scionti et al., 2012). The molecular criteria being contracted D4Z4
repeats on chromosomal haplotype 4qA161. As such we recommend additional sequencing
of patient DNA, with due consideration to the sequence identity and arrangement of the βsatellite to determine if there is a correlation between severity of disease, disease onset, or
disease presence or absence (asymptomatic FSHD). This may indicate differential efficiency
in the CPA of Dux4, and thus production of the somatically toxic gene.

Downstream Auxiliary Sequences aid cleavage and polyadenylation of Dux4PAS, but
is there more?
Although, we identify downstream sequences critical for production of a cleavage
product using the PAS-GFP reporter we failed to detect robust mRNA and protein
expression when the identified Dux4 CPA is placed downstream of the a reporter such as
mCherry. This suggests that there are additional requirements beyond the PAS and the
downstream auxiliary sequences. This is likely, because although the P200 construct
suppresses detection of the reporter protein in the PAS-GFP, we still detect an upstream
read-through product. However, it is unlikely that this read-through product is abundant as it
was detected only in the second round of PCR in the 3′ RACE. Moreover, the read-through
transcript, unlike the short upstream cleavage transcript, contains a stop codon and as such
is not susceptible non-stop decay (reviewed by (Klauer and van Hoof, 2012)) which would
reduce abundance. Further supporting low abundance of the read-through transcript in the
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P200 constructs, the P100, Exon 3 and pLAM constructs all produced a detectable readthrough transcripts in the first round of PCR.
While cloning the Dux4 PAS sequences required for CPA and reporter protein
expression we made an interesting observation: splicing upstream enhanced reporter
expression from the Dux4PAS. The observation that splicing affects CPA is not novel
(Kaida, 2016), however, when considering the architecture of the Dux4 gene, the
observation is intriguing. The Dux4 pre-mRNA has two introns in the untranslated region
(UTR). It had been previously demonstrated that the second intron causes the transcript to
be subject to nonsense mediated decay (Feng et al., 2015). However, the relevance of the
first intron which is retained in Dux4 isoform, Dux4Fl-1, had not been investigated. As
previously mentioned (see Chapter 2), a cryptic splice site within the first exon reportedly
generates a short isoform, Dux4-s which if translated would lack the C-terminal domain, and
may act as a dominant negative (Geng et al., 2012). Additionally, it has been observed by
others during an attempt to generate a transgenic Dux4 mouse containing the terminal D4Z4
repeat and abutting pLAM that there was frequent missplicing (Ansseau et al., 2015). Upon
analysis, we observe that the 5′ splice site after Dux4 exon 1 deviates 50% from the
consensus sequence bound by the U1snRNP. This poor splice site is likely in competition
with alternative sequences that have higher complementarity with the U1snRNP, and
consequently make better substrates for exon ligation, and we further posit that missplicing,
should it happen in patient cells, may contribute to the poor detection/expression of the
Dux4 mRNA.

Antagonizing Dux4 mRNA 3′ end formation
One of the primary goals of our investigation is to use Dux4PAS directed ASOs to
downregulate gene expression. One consideration for using ASOs is the accessibility of the
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target sequence. RNA molecules are not naked single stranded moieties in the cell, instead,
they adopt intricate secondary and tertiary structures by forming intra- and inter- molecular
bonds. Alternatively, or simultaneously RNA may be bound by proteins and packed into
ribonucleoproteins (RNPs). The result of this propensity to adopt secondary, tertiary and
quaternary structural conformations is that sequence elements targeted by antisense
oligonucleotides may be inaccessible. Consequently, the application and utility of ASO is
dependent on the stability and affinity of the interaction between RNA targets and non-ASO
molecules (proteins, RNA etc.). In addition, ASO utility and application is dependent on the
kinetics of the interactions. There are various strategies to limit these restrictions, but, for
use in therapeutics some of these options may be inapplicable. For example, increasing the
concentrations of ASO, increases the probability of ASO:RNA interactions, but may prove
toxic to patients. In another example, pretreating with ASOs prior to the activation of the
targeted event increases the likelihood of modulating the gene expression, however, this
would be a preventative measure rather than corrective.
Apart from consideration of accessibility to target by ASO, we should also consider
the implication of escape of targeted RNA from ASO. Here we use diphtheria toxin as an
example, wherein low expression of the diphtheria toxin (purportedly a single molecule) is
enough to cause toxicity (Murphy, 1996). By extension, we must address if this observation
is pertinent to Dux4, and to what extent must we reduce Dux4 for there to be a beneficial
effect. Dux4 expression is toxic to a wide variety of cells, with the possible exception of germ
cells (given the robust detection of Dux4 in the testicular tissue) (Kowaljow et al., 2007;
Snider et al., 2010). Given the stochastic and low expression of Dux4, we must ask how
many molecules of Dux4 are required to trigger Dux4-dependent pathologies. Although,
Dux4 mice do not recapitulate the full scope of FSHD, it has been shown that even leaky
expression of the protein can be lethal, and that surviving mice preferentially had the Dux4
gene silenced (Dandapat et al., 2014).
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Recently, others have demonstrated that Dux4PAS directed antisense
oligonucleotides can impair Dux4 expression in patient cells (Marsollier et al., 2016).
However, a global assessment of the effects of PAS directed ASOs, has not yet been
performed. The rationale for global assessment are (1) ASOs are generally very stable, and
stay in the cells for prolonged period and thus may have off-target effects (Bennett and
Swayze, 2010; Crooke, 2004). ASOs have also been shown to activate innate immunity
pathways (Agrawal and Kandimalla, 2004; Burel et al., 2012; Crooke, 2004; Senn et al.,
2005; Watts and Corey, 2012).
Successfully modulating gene expression with ASOs is empirical in both the clinic
and laboratory. Considerations for when using ASOs must include dosage frequency and
concentration and chemical modifications on the ASO to decrease toxicity while maintaining
efficacy (Crooke, 2004) amongst other thing. Yet another consideration, it that the clinical
response to use of antisense oligonucleotide therapies may be independent and distinct
from the response observed in the laboratory setting (reviewed by(Watts and Corey, 2012)).
As previously mentioned, ASOs can activate immune response pathways, due to triggering
interferon and extracellular signal–regulated kinases (ERKs) signaling (Burel et al., 2012;
Senn et al., 2005) and thus the utility of ASOs in mitigating the debilitating effects of one
disease is cancelled by the induction of acute inflammation. Furthermore, ASO delivery may
result in inappropriate organ targeting, and often hepatoxicity (Burel et al., 2016; Watts and
Corey, 2012). There is increased commercial availability of a variety of chemical
modifications for RNA or DNA based antisense oligonucleotides as well as the availability of
nucleoside analogues. Together with new modalities of ASO delivery the off target effects in
the clinical setting may be further reduced (Watts and Corey, 2012).
Using a reporter system where the Dux4 CPA is placed downstream of an introncontaining GFP, we have not been able to reproducibly deplete Dux4. 3′ RACE of the
reporter shows that there is another cleavage event upstream of the Dux4PAS which would
168

still generate GFP protein. In contrast, the SV40PAS only shows one cleavage event.
Others have shown that steric blocking ASOs can be used to redirect polyadenylation signal
choice and cleavage site (Marsollier et al., 2016; Vickers et al., 2001), and we reproduce
this effect. As such it is possible, that Dux4PAS-directed ASOs may redirect cleavage and
polyadenylation. However, the irreproducible decrease in reporter expression was observed
for both steric and gapmer ASO.
Continued investigation of the use of Dux4PAS directed ASOs is required, not only to
reproduce decrease in the gene expression, but also to address specificity. This would be
broadly applicable to any PAS-directed ASO therapeutic especially with the consideration of
causing alternative cleavage and polyadenylation.

Significance
Here we study the non-consensus PAS, AUUAAA, of Dux4 and interrogate the
adjacent sequences to identify cis elements that enhance cleavage and polyadenylation
from the Dux4PAS. The identification of downstream sequences in a degenerate repeat
(regardless of the distance from the PAS) is intriguing because of the implication that a lack
of consensus elements would allow for great variability in how this element mechanistically
aids cleavage and polyadenylation.
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